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A B S T R A C T
Background
The efficacy and safety of nipple-sparing mastectomy and areola-sparing mastectomy for the treatment of breast cancer are still
questionable. It is estimated that the local recurrence rates following nipple-sparing mastectomy are very similar to breast-conserving
surgery followed by radiotherapy.
Objectives
To assess the efficacy and safety of nipple-sparing mastectomy and areola-sparing mastectomy for the treatment of ductal carcinoma in
situ and invasive breast cancer in women.
Search methods
We searched the Cochrane Breast Cancer Group’s Specialized Register, the Cochrane Center Register of Controlled Trials (CENTRAL),
MEDLINE (via PubMed), Embase (via OVID) and LILACS (via Biblioteca Virtual em Saúde [BVS]) using the search terms “nipple
sparing mastectomy” and “areola-sparing mastectomy”. Also, we searched theWorld Health Organization’s International Clinical Trials
Registry Platform and ClinicalTrials.gov. All searches were conducted on 30th September 2014 and we did not apply any language
restrictions.
Selection criteria
Randomised controlled trials (RCTs) however if there were no RCTs, we expanded our criteria to include non-randomised comparative
studies (cohort and case-control studies). Studies evaluated nipple-sparing and areola-sparing mastectomy compared to modified radical
mastectomy or skin-sparing mastectomy for the treatment of ductal carcinoma in situ or invasive breast cancer.
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Data collection and analysis
Two review authors (BS and RR) performed data extraction and resolved disagreements. We performed descriptive analyses and meta-
analyses of the data using Review Manager software. We used Cochrane’s risk of bias tool to assess studies, and adapted it for non-
randomised studies, and we evaluated the quality of the evidence using GRADE criteria.
Main results
We included 11 cohort studies, evaluating a total of 6502 participants undergoing 7018 procedures: 2529 underwent a nipple-sparing
mastectomy (NSM), 818 underwent skin-sparing mastectomy (SSM) and 3671 underwent traditional mastectomy, also known as
modified radical mastectomy (MRM). No participants underwent areola-sparing mastectomy. There was a high risk of confounding
for all reported outcomes. For overall survival, the hazard ratio (HR) for NSM compared to SSM was 0.70 (95% CI 0.28 to 1.73; 2
studies; 781 participants) and the HR for NSM compared to MRM was 0.72 (95% CI 0.46 to 1.13; 2 studies, 1202 participants).
Local recurrence was evaluated in two studies, the HR for NSM compared to MRM was 0.28 (95% CI 0.12 to 0.68; 2 studies, 1303
participants). The overall risk of complications was different in NSM when compared to other types of mastectomy in general (RR
0.10, 95% CI 0.01 to 0.82, 2 studies, P = 0.03; 1067 participants). With respect to skin necrosis, there was no evidence of a difference
with NSM compared to other types of mastectomy, but the confidence interval was wide (RR 4.22, 95% CI 0.59 to 30.03, P = 0.15; 4
studies, 1948 participants). We observed no difference among the three types of mastectomy with respect to the risk of local infection
(RR 0.95, 95%CI 0.44 to 2.09, P = 0.91, 2 studies; 496 participants). Meta-analysis was not possible when assessing cosmetic outcomes
and quality of life, but in general the NSM studies reported a favourable aesthetic result and a gain in quality of life compared with the
other types of mastectomy. The quality of evidence was considered very low for all outcomes due to the high risk of selection bias and
wide confidence intervals.
Authors’ conclusions
The findings from these observational studies of very low-quality evidence were inconclusive for all outcomes due to the high risk of
selection bias.
P L A I N L A N G U A G E S U M M A R Y
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Review question
We reviewed the evidence about the effectiveness and safety of nipple-sparing mastectomy (that is, removing the breast tissue but
preserving the entire skin, nipple and areola) compared to traditional mastectomy (that is, removing the skin that overlies the breast
including nipple and areola) or skin-sparingmastectomy (that is, removing the breast tissue including the breast and areola but preserving
all the skin envelope).
Background
Traditional surgical therapy for breast cancer is mastectomy. A traditional mastectomy consists of the removal of the entire breast tissue
and the nipple-areola complex. The chance of cancer returning to the region of the mastectomy after this type of surgery is about 2.3%
after 20 years. Rising interest in improving the cosmetic results has led to the introduction of nipple-sparing mastectomy or areola-
sparing mastectomy as an alternative to conventional mastectomy. Nipple-areola complex preservation results in higher psychological
satisfaction and the perception of less mutilation among women. Nipple-sparing mastectomy has been proposed for the treatment of
breast cancer. This technique retains the entire natural envelope of the skin and areola complex, and aims to create an aesthetic result
that is closer to the natural state than breast reconstruction techniques. The efficacy and effectiveness of nipple- and areola-sparing
mastectomy in the treatment of breast cancer is questionable.
Study characteristics
The evidence is current to September 2014. We included 11 studies involving 6502 participants having 7018 surgical procedures (some
participants had surgery on both breasts). Out of these, 2529 participants underwent nipple-sparing mastectomy, while there were
no participants who had an areola-sparing mastectomy, 818 participants underwent skin-sparing mastectomy and 3671 underwent a
traditional mastectomy. All participants in the studies were women and most of them (99.2%) had invasive breast cancer or ductal
carcinoma in situ. We compared nipple-sparing mastectomy to conventional mastectomy and skin-sparing mastectomy in two different
analyses.
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Key results
It was not possible to conclude whether or not survival following nipple-sparing mastectomy was similar to traditional mastectomy and
skin-sparing mastectomy. Results were also inconclusive for differences in local recurrence and adverse events following different types
of mastectomy. In practice the decision to select nipple-sparing mastectomy over other types of mastectomy should be done through
shared decision making after extensive discussion of the risks and benefits. Generally the nipple-sparing mastectomy studies reported
a favourable aesthetic result and a gain in quality of life compared with the other types of mastectomy. However, due to the lack of
numerical data, it was not possible to pool the results of different studies.
Quality of the evidence
The quality of the evidence included in this review was very low. The studies had a number of methodological flaws. Poor reporting
meant that the effect of the type of mastectomy on survival could not be determined for a number of studies. Also, differences between
surgery groups in tumour stage and whether or not adjuvant radiotherapy was used may have affected the results. This is likely to have
an impact on the findings and future research is likely to change the current findings.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Nipple-sparing mastectomy for breast cancer treatment
Patient or population: women with breast cancer
Setting: breast cancer therapy centres
Intervention: nipple-sparing mastectomy
Comparison: modif ied radical mastectomy
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with other types of
mastectomies
Risk with nipple-spar-
ing mastectomy
Overall survival Study populat ion HR 0.72
(0.46 to 1.13)
1202
(2 observat ional stud-
ies)
⊕©©©
VERY LOW1,2
We were unable to con-
clude non-inferiority be-
cause of the high risk of
confounding. The qual-
ity of evidence was
downgraded to very low
due to the risk of bias
and imprecision
882 per 1000 785 per 1000
(626 to 910)
Local recurrence Study populat ion HR 0.28
(0.12 to 0.68)
1311
(2 observat ional stud-
ies)
⊕©©©
VERY LOW 3
Conclusions could not
be drawn because of
the high risk of residual
confounding. The qual-
ity of the evidence was
graded as very low due
to the risk of bias
17 per 1000 5 per 1000
(2 to 12)
Overall complicat ions Study populat ion RR 0.10
(0.01 to 0.82)
1067
(2 observat ional stud-
ies)
⊕⊕©©
LOW 4
We downgraded the
quality of evidence
f rom low to very low
due to inconsistency (i.
e. the magnitude of ef -
fects across the stud-
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ies)
184 per 1000 18 per 1000
(2 to 151)
Skin necrosis Study populat ion RR 4.22
(0.59 to 30.03)
1948
(4 observat ional stud-
ies)
⊕©©©
VERY LOW 5,6
We downgraded the
quality of evidence
f rom low to very low due
to a wide conf idence in-
terval
19 per 1000 82 per 1000
(11 to 583)
Infect ion Study populat ion RR 0.95
(0.44 to 2.09)
496
(2 observat ional stud-
ies)
⊕⊕©©
LOW
48 per 1000 45 per 1000
(21 to 100)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io; HR: Hazard rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1There was no adjustment for confounding in Sakurai 2013 and we classif ied this as a serious risk of bias. We we were unable
to conclude non-inferiority because of the high risk of confounding
2The conf idence interval of included studies both increased and decreased risk for nipple-sparing mastectomy versus modif ied
radical mastectomy
3Imprecision was downgraded because of the high risk of residual confounding due to lack of adjustment for tumour stage
and radiotherapy. Adam 2014 matched the part icipants by tumour stage, Horiguchi 2001 seemed to have more init ial tumours
(Stages 0 and 1) in the NSM group (83 out of 123; 67.5%) than the MRM group (277 out of 910; 30.4%) and this fact may have
inf luenced the results. Only 7.9% (103 out of 1303 part icipants) received radiotherapy, 7.2% (81 out of 1113 part icipants) in
the modif ied radical mastectomy group and in 11.6% (22 out of 190 part icipants) in the nipple-sparing mastectomy. No one
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received the treatment in Horiguchi 2001, probably because in that period the indicat ion for radiotherapy treatment was more
lim ited. Probably more pat ients would now receive post-mastectomy radiotherapy, which would have an impact on the local
recurrence rate
4There was evidence of considerable heterogeneity on stat ist ical test ing, I2 = 85%, P = 0.01
5There was evidence of considerable heterogeneity on stat ist ical test ing, I2 = 79% , P = 0.008
6Conf idence intervals fail to exclude both clinically important and clinically unimportant harms.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Breast cancer is themost frequent non-skin cancer inwomen (23%
of all cancers in women) with an estimated 1.67 million new
cases and over 521,907 deaths reported worldwide in 2014 (Ferlay
2012).
Description of the intervention
The technique of subcutaneous mastectomy for the treatment of
benign breast disease for women with a strong family history of
breast cancer was first reported by Freeman 1962. In 1980, Gentil
1980 proposed nipple-sparing mastectomy (NSM) for prophylac-
tic contralateral mastectomy and to treat breast cancer. The tradi-
tional method of mastectomy consists of the removal of the skin
that overlies the breast including the nipple-areola complex. To-
day, NSM is commonly used for women who are considered to be
high risk and who are undergoing surgery as primary prevention
for breast cancer (Hartmann 2001; Josephson 2000; Lostumbo
2010; Pennisi 1989).
How the intervention might work
The surgical management of breast carcinoma has evolved during
the last two decades and improvements in the techniques mean
that more conservative surgery and better cosmetic results can
be achieved without compromising oncological safety (Morrow
2002). Although the techniques for breast conserving surgery in
the treatment of breast cancer are well-established, many women
prefer or require mastectomy to obtain local control of their dis-
ease. This is particularly true in cases of multifocal tumours and/
or small volume breasts in relation to the tumour, extensive ductal
carcinoma in situ, women with clinical contraindications for ra-
diotherapy and treatment of local recurrences (Singletary 2003).
Conventional surgical therapy in these situations is mastectomy
with the removal of the nipple-areola complex. This type of surgery
has a cumulative incidence of local recurrence of about 2.3% after
20 years (Veronesi 1990).
Rising interest in improved cosmesis (i.e. cosmetic outcome) has
led to the introduction of NSM or areola-sparing mastectomy as
an alternative to radical mastectomy (Chung 2008; Gerber 2009;
Simmons 2002). Nipple-areola complex preservation results in
higher psychological satisfaction and the perception of less muti-
lation among women (Loewen 2008).
Occult nipple involvement in breast cancer ranges from 0% to
58% (Andersen 1979; Banerjee 2008; Lagios 1979; Laronga 1999;
Loewen 2008; Luttges 1987;Menon 1989;Morimoto 1985; Parry
1977; Quinn 1981; Rusby 2008; Santini 1989; Schecter 2006;
Smith 1976; Verma 1997; Vyas 1998; Wetheim 1980) and are-
ola involvement is 0.9% in people with tumours less than 2 cm
(Simmons 2002). This wide range may be explained by differ-
ences in the thoroughness of the pathological examinations and
the study methods. The factors most commonly associated with
the pathological involvement of the nipple are the size and re-
gion of the tumours, the distance of the tumours from the nipple,
and axillary metastasis (Benediktsson 2008; Caruso 2006; Lagios
1979; Schecter 2006).
Despite the promising approach with nipple-sparing and areola-
sparing mastectomy, the evidence from published studies seems
preliminary. These studies include a small number of partici-
pants and a relatively short follow-up period (Benediktsson 2008;
Caruso 2006;Gerber 2009;Horiguchi 2001; Petit 2009a; Sacchini
2006). In these non-randomised studies, the incidence of lo-
cal recurrence ranges from 1.6% to 28% without radiotherapy
(Benediktsson 2008; Caruso 2006), and 1.4% to 8.5% with ra-
diation of the nipple-areola complex (Benediktsson 2008; Petit
2009a; Petit 2009b). Surgical complications such as skin necrosis
(i.e. death of localised tissue or cells) have been described in up to
11% of patients without radiotherapy (Sacchini 2006) and up to
15% with the addition of radiotherapy to the nipple-areola com-
plex (Petit 2009a).
Why it is important to do this review
NSM has been proposed for the treatment of breast cancer. This
technique retains the entire natural envelope of the skin and areola
complex, and aims to create an aesthetic result that is closer to
the natural state than breast reconstruction techniques. The effi-
cacy and effectiveness of NSM in the treatment of breast cancer is
questionable, but it is estimated that local recurrence rates are very
similar to those for breast-conserving surgery followed by radio-
therapy (Veronesi 1990; Veronesi 2002). No systematic reviews or
articles have been published that have assessed the relevant studies
with regards to their internal and external validity, and the risk of
bias. Therefore, a systematic review on this topic is warranted.
O B J E C T I V E S
To assess the efficacy and safety of nipple-sparing mastectomy and
areola-sparing mastectomy for the treatment of ductal carcinoma
in situ and invasive breast cancer in women.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We searched for randomised controlled trials (RCTs) as they pro-
vide the highest level of evidence. As no RCTs were found, we ex-
panded our criteria to include non-randomised comparative stud-
ies (cohort and case-control studies).
Types of participants
Women with a diagnosis of ductal carcinoma in situ or invasive
breast cancer, regardless of age, time of onset, or disease stage. The
diagnosis must have been in accordance with the histopathologi-
cal criteria of the World Health Organization (WHO) (Lakhani
2012).
We included women who had undergone breast reconstructive
surgery.
Types of interventions
Nipple-sparingmastectomy (NSM) (that is, removal of all glandu-
lar breast tissue and preservation of the entire skin, nipple and are-
ola) and areola-sparing mastectomy (that is, removal of all glandu-
lar breast tissue and nipple, and preservation of the entire skin and
areola) compared with conventional mastectomy (removal of the
skin that overlies the breast including the nipple and areola, also
known as modified radical mastectomy (MRM)) for the treatment
of ductal carcinoma in situ or invasive breast cancer, regardless of
any adjuvant therapy.
We included studies where women underwent breast reconstruc-
tive surgery.
Types of outcome measures
Primary outcomes
Overall survival, considered separately for ductal carcinoma in situ
and early breast cancer if possible.
Secondary outcomes
• Local recurrence incidence rate and time-to-recurrence
during the follow-up period, considered separately for ductal
carcinoma in situ and early breast cancer if possible.
• Adverse events: local surgical complications and overall
complications (systemic surgical complications, e.g.
thromboembolic events)
◦ Local Complications
⋄ Explantation of implant/expander
⋄ Hematoma
⋄ Seroma
⋄ Rehospitalization
⋄ Skin necrosis (nipple, areola or flap necrosis)
⋄ Skin necrosis with revision surgery
⋄ Infection
• Cosmetic results: participants’ and professionals’ opinions
• Quality of life including satisfaction with the decision to
have NSM, satisfaction with the cosmetic outcome, satisfaction
with the medical process, psychological well-being, impact on
body image, and impact on primary relationships and sexuality.
Search methods for identification of studies
See: Breast Cancer Group for search methods used in reviews.
There were no language restrictions on included studies. We un-
dertook full translations of all non-English language papers using
local resources.
Electronic searches
We searched the following databases.
• The Cochrane Breast Cancer Group’s Specialised Register.
The Cochrane Breast Cancer Group searched their Specialised
Register on 30 September 2014. Details of the search strategies
used by the Group for the identification of studies and the
procedure used to code references are outlined in the Group’s
module (onlinelibrary.wiley.com/o/cochrane/clabout/articles/
BREASTCA/frame.html). We extracted trials with the key words
’surgery’, ’nipple sparing mastectomy’, ’areola sparing
mastectomy’ and ’breast conserving surgery’
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2014, issue 9) (Appendix 1)
on 30 September 2014.
• MEDLINE (via Pubmed) (Appendix 2) on 30 September
2014.
• Embase (via OVID) (Appendix 3) on 30 September 2014.
• LILACS (via Biblioteca Virtual em Saúde (BVS))
(Appendix 4) on 30 September 2014.
• The WHO International Clinical Trials Registry Platform
(ICTRP) search portal (www.who.int/ictrp/en/) for all
prospectively registered and ongoing trials (Appendix 5) on 30
September 2014.
• ClinicalTrials.gov (www.clinicaltrials.gov/) (Appendix 6) on
30 September 2014.
Searching other resources
Bibliography Searching
We searched bibliographies of all included studies and review pa-
pers in order to identify other potentially suitable studies. We ob-
tained a copy of the full article for each reference reporting a po-
tentially eligible trial, where possible. We contacted the study au-
thors to provide additional information when it was not available.
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Unpublished Literature
We contacted experts in this field and sent letters to all authors of
included studies requesting information on unpublished data or
ongoing studies.
Data collection and analysis
Selection of studies
Two review authors (BS, RR) independently examined the titles
and abstracts of articles identified in the search as potentially rele-
vant trials. From this initial assessment, we obtained full versions
of all potentially relevant articles. We consulted a third review au-
thor (JLBB) to help to resolve any disagreements.
Data extraction and management
We extracted and recorded the data onto data extraction forms
which we had developed for this review. Two review authors (BS
and RR) independently undertook full data extraction and con-
sulted a third review author (JLBB) to help resolve disagreements.
We sought unpublisheddata concerning outcomes of interest from
study authors by letter as stated above.
We included the following information from individual studies
on data extraction forms:
• publication details;
• study design, study setting, inclusion/exclusion criteria;
• patient population (e.g. age, type of surgical procedure,
histological classification);
• details of intervention;
• outcome measures; and
• withdrawals, length and method of follow-up and the
number of participants followed up.
For non-randomised studies we also recorded the following infor-
mation:
• methods used to control for confounders;
• adjusted and unadjusted outcome measures.
Assessment of risk of bias in included studies
We applied theCochrane tool for assessing risk of bias as described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011a), the Cochrane EPOC Group’s risk of bias cri-
teria (Cochrane EPOC Group 2013), and recommendations by
Norris 2013. Two review authors (BS, RR )independently assessed
the methodological quality of each study and risk of bias for the
following domains: selection bias, performance/detection bias, at-
trition bias, reporting bias and other bias. For each risk of bias
domain and its associated specific questions outlined below, we
assigned either ’High risk’, ’Low risk’, or ’Unclear risk’.
Selection Bias
Was the allocation sequence adequately generated?
• Scored “Low risk” if a random component in the sequence
generation process was described (e.g. referring to a random
number table).
• Scored “High risk” when a non-random method was used
(e.g. performed by date of admission). Non-randomised studies
should be scored “High risk”.
• Scored “Unclear risk” if not specified in the paper.
Was the allocation adequately concealed?
• Scored “Low risk” if participants or investigators enrolling
participants could not foresee assignment (e.g. because a
centralised randomisation scheme, an on-site computer system
or sealed opaque envelopes were used).
• Scored “High risk” if participants or investigators enrolling
participants could possibly foresee assignments. Non-
randomised studies were scored “High risk”.
• Scored “Unclear risk” if not specified in the paper.
For non-randomised studies, we also considered the following
questions.
Were baseline characteristics similar?
• Scored “Low risk” if baseline characteristics of the study and
control group were reported and similar. Important baseline
characteristics were adjuvant radiotherapy, age, surgical
techniques, stage of disease, ductal carcinoma in situ or invasive
breast cancer, and chemotherapy. We considered intervention
and control groups similar for categorical variables if category
membership agreed within no more than a 2 percentage point
difference between groups. We considered mean ages within two
years and tumour sizes within 1 cm similar. When we used
statistical tests to compare baseline characteristics between
groups, we took statistical significance into account, but as the
study may have been underpowered due to small sample sizes, we
also considered the magnitude of the difference.
• Scored “Unclear risk” if it was not clear in the paper (e.g.
characteristics were mentioned in the text, but no data were
presented).
• Scored “High risk” if there was no report of characteristics
in text or tables or if there were differences between control and
intervention groups.
Was there adequate adjustment for confounding?
• Scored “Low risk” if appropriate methods were used to
adjust for potential confounding (e.g. adjuvant radiotherapy, age,
surgical techniques, stage of disease, ductal carcinoma in situ or
invasive breast cancer, and chemotherapy).
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• Scored “Unclear risk” if the methods used to adjust for
confounding were not reported in the paper.
• Scored “High risk” if no appropriate methods were used to
adjust for potential confounding.
Performance/detection bias
Was knowledge of the allocated interventions adequately
prevented during the study?
• Scored “Low risk” if the study authors stated explicitly that
the primary outcome variables were assessed blindly, or the
outcomes were objective, e.g. overall survival, hospitalisation
time
• Scored “High risk” if the outcomes were not assessed blindly
• Scored “Unclear risk” if not specified in the paper
Attrition bias
Were incomplete outcome data adequately addressed?
• Scored “Low risk” if missing outcome measures were
unlikely to bias the results (e.g. reasons for missingness unlikely
to be related to true outcome, missing outcome data balanced
and small numbers across study groups with similar reasons for
missing data or missing data were imputed using appropriate
methods).
• Scored “High risk” if missing outcome data were likely to
bias results.
• Scored “Unclear risk” if not specified in the paper.
Reporting bias
Were reports of the study free from selective outcome
reporting?
• Scored “Low risk” if there was no evidence that outcomes
were selectively reported (e.g. the study had a protocol pre-
specifying the outcomes, or all relevant outcomes described in
the methods section were reported in the results section).
• Scored “High risk” if some pre-specified outcomes were
subsequently omitted from the results.
• Scored “Unclear risk” if not specified in the paper.
Were reports of the study free from selective analysis
reporting?
• Scored “Low risk” for each outcome if there was no
evidence that analyses were selectively reported (e.g. analyses
were defined in the methods section of the protocol or paper).
• Scored “High risk” if there was evidence of selective analysis
reporting (e.g. multiple adjusted analyses were carried out and
only one reported, or unusual cut-points were used for
categorizing an outcome).
• Scored “Unclear” risk if unclear from the paper.
Classification of study designs
We included various study designs and defined them as follows:
• Prospective cohort study: a group of exposed and non-
exposed individuals who were followed over time to compare
incidence (or rate of death from disease) between the groups
(Gordis 1996). In prospective cohort studies, the recruitment,
exposure/intervention, and outcomes must all have occurred
after setting up the study.
• Retrospective cohort study: a group of exposed and non-
exposed individuals who were followed over time to compare
incidence (or rate of death from disease) between the groups
(Gordis 1996). In retrospective cohort studies, outcomes could
have occurred prior to setting up the study or collected
afterwards, or both.
• Case-control study: a study that compared people with a
specific outcome of interest (cases) with people from the same
source population but without the outcomes (controls), to
examine the association between the outcome and exposure.
Measures of treatment effect
Wereported time-to-event outcomes (e.g. overall survival and local
recurrence) as hazard ratios (HRs) with 95% confidence intervals
(CIs). Where necessary we estimated HRs using the methods of
Parmar 1998.
We reported dichotomous outcomes (e.g. distant disease, explan-
tation of implant/expander, hematoma, seroma, rehospitalization,
skin necrosis (nipple, areola or flap necrosis), skin necrosis (nip-
ple, areola or flap necrosis) with revision surgery, infection and
cosmetic results) as risk ratios (RRs) with 95% CIs. Participants
reported as lost-to-follow-up were excluded from the analyses.
We reported continuous outcomes (e.g. quality of life) as mean
differences (MDs) or standardised mean differences (SMD) with
95% CIs.
Considering the current approach for ductal carcinoma in situ or
invasive breast cancer, it seemed reasonable to consider the treat-
ment effect for the primary outcome as a non-inferiority question.
Thus, the non-inferiority bound for the HR was 1.13 (based on
a 10-year death rate of 24% for conventional mastectomy with a
cut-off value of 27% for nipple/areola-sparing mastectomy, 1.13 =
0.27/0.24). For local recurrence the non-inferiority bound for the
HR was 2.67 (based on 3% 10-year local recurrence for conven-
tional mastectomy with a cut-off value of 8% for nipple/areola-
sparing mastectomy, 2.67 = 0.08/0.03). Non-inferiority could be
claimed if the upper limit of the two-sided 95% confidence inter-
val was less than the non-inferiority bound.
Outcomes relating to adverse events were assessed for superiority.
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Unit of analysis issues
The unit of analysis was the individual participant.
Two studies were three-arm studies. The three surgical interven-
tions in the Gerber 2009 and Kim 2010 studies contributed to the
NSM versus SSM comparison and also the NSM versus MRM
comparison.
Dealing with missing data
Where data were missing or unsuitable for analysis (e.g. intention-
to-treat analysis was not used), we contacted the study authors to
request further information as indicated in the Characteristics of
included studies table. Where data were missing to the extent that
the study could not be included in themeta-analysis, and attempts
to retrieve data were exhausted, we presented the results in the
review and discussed them in the context of the findings.
Assessment of heterogeneity
We assessed statistical heterogeneity using the Chi2 statistic (P
value less than 0.1).We also assessed heterogeneity between studies
using the I2 statistic to examine the percentage of total variation
across studies due to heterogeneity rather than chance (Higgins
2003). An I2 value of 30% to 60% may represent moderate het-
erogeneity, while values greater than 50% may be considered sub-
stantial heterogeneity (Deeks 2011).
We investigated the following factors as potential causes of het-
erogeneity in the included studies using the framework below.
• Clinical diversity: included study location and setting, full
characteristics of participants, co-morbidity and treatments that
participants were probably receiving on trial entry. We
considered how outcomes were measured, the definition of
outcomes, and how they were recorded. Depending upon the
extent of the clinical diversity, we either analysed studies
separately or presented the results using a narrative approach.
• Methodological diversity: included assessment of the
randomisation process, study quality, and analytical method.
Assessment of reporting biases
We searched for protocols of included trials using PubMed (Na-
tional Library of Medicine) and through the UK and other trial
registries, where possible. We contacted study authors to attempt
to establish a full data set or reasons for the non-reporting of cer-
tain outcomes as outlined in theCharacteristics of included studies
table.
Data synthesis
We synthesised data using Cochrane’s statistical software, Review
Manager (RevMan) (RevMan 2014).
Webased the choice of using a fixed-effect or random-effectsmodel
for data synthesis on the extent of the heterogeneity. Where sub-
stantial clinical or methodological heterogeneity existed, we used
a random-effects model. Otherwise we used a fixed-effect model
(Deeks 2011).
We combined data using the inverse variance method and the
log-HR for time-to-event outcomes, the log-RR for dichotomous
outcomes and the MD for continuous outcomes. For random-
effects meta-analysis we used the DerSimonian and Laird method
(Deeks 2011).
Where the data were too diverse for combining effect sizes in a
meaningful or valid manner, we presented the results of individual
studies in table and graphical format and used a narrative approach
to summarise the data.
We used the criteria of the GRADE working group to evaluate the
evidence. The quality of evidence for each outcomewas classified as
high, moderate, low or very low quality. The classification criteria
considered the study design, the risk of bias, the inconsistency of
data, subjectivity (indirectness, or indirect evidence), imprecision
and publication bias (Guyatt 2008).
Subgroup analysis and investigation of heterogeneity
Aswe expected a small number of published studies, we anticipated
that it would not be possible to perform subgroup analyses.
However, we will consider the following subgroups in future up-
dates of this review.
• Participants who received adjuvant radiotherapy versus
participants who did not have radiotherapy.
• Younger (< 50 years ) versus older (≥ 50 years) women.
• Surgical techniques.
• Cancer stage based on the TNM (the size and/or extent of
the primary tumour (T), the amount of spread to nearby lymph
nodes (N), and the presence of metastases (M) or secondary
tumours) classification system (NCI 2013).
• Systemic therapy (chemotherapy or endocrine therapy)
versus no systemic therapy.
Sensitivity analysis
We planned to conduct sensitivity analyses by excluding either
studies of low methodological quality or, if RCT evidence was
available, quasi-randomised studies. This was not possible due to
a lack of good quality studies, but will be considered for future
updates of this review.
R E S U L T S
Description of studies
Results of the search
See: Figure 1.
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Figure 1. Study flow diagram
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Based on our search strategy, we identified and screened 5130
references, with an additional six references identified from other
sources. After removing duplicates, we screened the title and ab-
stracts of 3662 references. Of these, we discarded 3610 records
and assessed 52 full-text articles. We excluded 41 articles due to
being either case series or duplicate data. Eleven cohort studies
met the inclusion criteria for this review. There were no RCTs or
quasi-RCTs.
Included studies
We included 11 studies in the review (Adam 2014; Boneti 2011;
Burdge 2013; Gerber 2009; Horiguchi 2001; Kim 2010; Oura
1994; Poruk 2015; Sakurai 2013; Shi 2012; Stanec 2014). See:
Characteristics of included studies table.
Study design
All studies were cohort studies; 10 were retrospective (Adam 2014;
Boneti 2011; Burdge 2013; Horiguchi 2001; Kim 2010; Oura
1994; Poruk 2015; Sakurai 2013; Shi 2012; Stanec 2014) and one
was prospective (Gerber 2009).
Characteristics of participants
In total, the studies included 6502 participants involving 7018
procedures, as 516 participants underwent bilateral surgery. Out
of these, 2529 participants underwent nipple-sparing mastectomy
(NSM), while there were no participants who had areola-spar-
ing mastectomy, 818 participants underwent skin-sparing mastec-
tomy (SSM) and 3671 underwent a modified radical mastectomy
(MRM).
The mastectomy indications were 99.2% for invasive breast car-
cinoma or ductal carcinoma in situ and 0.8% for prophylaxis,
that mostly involved the contralateral breast after invasive breast
cancer. It was possible to identify the indications for NSM in 10
studies.
The criteria for mastectomy varied across the included studies.
In six studies, the criteria comprised any tumour without skin or
areola involvement (Boneti 2011; Burdge 2013; Kim 2010; Poruk
2015; Sakurai 2013; Shi 2012). Four studies considered tumours
located at least 2 cm from the nipple-areola complex (Adam 2014;
Gerber 2009; Oura 1994; Stanec 2014).
Eleven studies classified the stage of the tumour. Eight studies
used the AJCC classification (Gerber 2009; Horiguchi 2001; Kim
2010; Oura 1994; Poruk 2015; Sakurai 2013; Shi 2012; Stanec
2014). In total, 387 participants had Stage 0, 1992 participants
had stage 1; 2776 participants had stage 2; 655 participants had
stage 3 and 11 participants had stage 4 tumours (refer to Table 1).
In the three remaining studies, one study (Burdge 2013) enrolled
participants with, at least, stage 2 (NSM: mean tumour size was
3.4 cm (± 2.2 cm) and SSM: mean tumour size was 4.6 cm (±
2.9 cm)). The Boneti 2011 study described the mean tumour size
and there was no difference between groups (the mean tumour
size was 1.9 cm (± 1.6 cm) in the NSM group and 2.1 cm (± 1.7
cm) in the SSM group, P = 0.42 in SSM group) and Adam 2014
described the tumour size according to TNM staging (NSM: T1 -
37 participants (53.6%), T2 - 14 participants (20.3%), T3 - three
participants (4.3%), T4 - one participant (1.4%); MRMT1 - 111
participants (53.9%), T2 - 46 participants (22.3%), T3 - nine
participants (4.4%), T4 - one participant (0.5), P = 0.86). In two
studies therewere significant differences in staging between groups
with more advanced disease in the SSM group (Poruk 2015) and
MRM group (Horiguchi 2001) when compared toNSM. In six of
the remaining studies there were differences between intervention
and control groups of more than 2 percentage points for at least
one tumour stage (Gerber 2009; Kim 2010; Oura 1994; Sakurai
2013; Shi 2012; Stanec 2014) (Table 2). Only two studies used
appropriate methods to adjust for tumour stage (Kim 2010; Poruk
2015), while Adam 2014matched participants in the intervention
and control groups according to their tumour stage.
The mean age was described in 10 studies while one study
(Horiguchi 2001) described the age groups as younger or older
than 50 years (see Table 3). Two studies reported similar ages be-
tween intervention and control groups (Adam 2014; Boneti 2011).
Three studies reported significant differences between groups
(Gerber 2009;Horiguchi 2001; Poruk 2015)with theNSMgroup
being younger on average. The remaining five studies reported
more than two years’ difference in mean age between intervention
and control groups (Burdge 2013; Oura 1994; Sakurai 2013; Shi
2012; Stanec 2014). Only three studies used appropriate methods
to adjust for tumour stage disease (Horiguchi 2001; Kim 2010;
Poruk 2015). One study matched participants in the intervention
and control groups according to three age categories (Adam 2014).
Interventions
Five studies compared NSM and MRM (Adam 2014; Horiguchi
2001;Oura 1994; Sakurai 2013; Shi 2012), four studies compared
NSM and SSM (Boneti 2011; Burdge 2013; Poruk 2015; Stanec
2014) and two studies contained three arms involving NSM, SSM
and MRM (Gerber 2009; Kim 2010).
Regarding adjuvant therapy, only two studies described chemo-
therapy (Gerber 2009; Poruk 2015). Poruk 2015 reported that
use of both neoadjuvant and adjuvant chemotherapy was higher
in the SSM group (neoadjuvant: 17%: 22/131 participants and
adjuvant: 57%: 74/131 participants) compared to the group re-
ceiving NSM (neoadjuvant: 8.5%: 11/130 participants and adju-
vant: 44.5%: 57/130; P = 0.04 and 0.05, respectively). There was
no difference between NSM and SSM groups for neo- or adjuvant
chemotherapy in Gerber 2009: 90% (43/48 participants) in the
NSM group versus 88% (53/60) in the SSM group, but it was
lower in the MRM group: 83% (109/130).
Radiotherapy was a co-intervention in seven studies. In five stud-
ies, radiotherapy was performed according to tumour stage (Adam
2014; Boneti 2011; Gerber 2009; Poruk 2015; Stanec 2014). In
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the remaining two studies, all participants received radiotherapy
(Burdge 2013; Shi 2012). Only two studies compared radiother-
apy between intervention groups. Poruk 2015 reported 28% of
radiotherapy treatment (36 out of 130 participants) for the NSM
group versus 50.4% (65 out of 131 participants) for the SSM
group (P < 0.001). Gerber 2009 did not find a difference in ra-
diotherapy treatment between the NSM and SSM groups: 29%
(14 out of 48 participants) and 27% (16 out of 60 participants)
respectively, but it was lower for the MRM group: 24% (31 out
of 130 participants).
In three studies, participants did not receive radiotherapy (
Horiguchi 2001; Oura 1994; Sakurai 2013).
Follow-up
Six studies had a mean follow-up of 60 months or greater (Gerber
2009; Horiguchi 2001; Kim 2010; Oura 1994; Sakurai 2013;
Shi 2012). The shortest follow-up ranged from 3 to 102 months
(mean: 25.3 months; Boneti 2011) while the longest ranged from
0 to 231 months (mean: 87 months; Sakurai 2013). Boneti 2011
used methods to adjust for differential follow-up between inter-
vention and control groups; this study had a mean follow-up of
25.3 months for the NSM group and 38.2 months for the SSM
group (P < 0.001). (See Table 4.)
Excluded studies
Of the 41 excluded studies, all were case series with two being
duplicate reports. See Excluded studies.
Risk of bias in included studies
The risk of bias for each of the selected studies is shown in Figure
2. Overall, we identified 11 relevant studies (11 cohort ) published
between 2001 and 2014. The major implication for risk of bias
assessment was selection bias due to the lack of random assignment
to interventionor control.None of the studies performed adequate
adjustment for confounding, and there were differences in baseline
characteristics between intervention and comparison groups for
some studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The most common source of potential bias was selection bias. All
studies were cohort studies; 10 were retrospective (Adam 2014;
Boneti 2011; Burdge 2013; Horiguchi 2001; Kim 2010; Oura
1994; Poruk 2015; Sakurai 2013; Shi 2012; Stanec 2014) while
one was prospective (Gerber 2009). Therefore none had an alloca-
tion sequence adequately generated and concealed, and so all were
judged as having a high risk of bias.
Differences in baseline characteristics betweenmastectomy groups
were observed for nine studies (Burdge 2013; Gerber 2009;
Horiguchi 2001; Kim 2010; Oura 1994; Poruk 2015; Sakurai
2013; Shi 2012; Stanec 2014). For two studies (Adam 2014;
Boneti 2011) the stage of disease and age at baseline of participants
were similar, but differences in chemotherapy and radiotherapy
between groups were not reported.
None of the studies used appropriate techniques to deal with all the
potential confounders that were pre-specified for this review. Some
studies partially adjusted for confounding. Adam 2014 matched
participants for age, tumour stage and follow up, but made no
adjustment for adjuvant radiotherapy, surgical techniques or che-
motherapy. Horiguchi 2001 adjusted for age, lymph node status
and oestrogen receptor status for local recurrence, but did not ad-
just for tumour stage, surgical techniques or chemotherapy. Kim
2010 adjusted overall survival for age, tumour stage and oestrogen
receptor status, but did not adjust for radiotherapy use, surgical
techniques or chemotherapy use. Poruk 2015 controlled for age,
stage, and surgery laterality, but did not adjust for radiotherapy
or chemotherapy use. The remaining studies made no adjustment
for confounding.
Blinding
Blinding of participants and surgeons was not possible because
of the nature of the procedure. The lack of blinding may have
influenced the results for some outcomes. The time to event out-
comes were judged as low risk of bias. Adverse events, cosmesis
and quality of life were judged as high risk of bias due to the lack
of blinding.
Incomplete outcome data
Three studies reported loss-to-follow-up. Stanec 2014 reported
almost 12%, which may have been high enough to influence re-
sults, so the risk of bias was considered to be unclear, Boneti 2011
reported 5% and Gerber 2009 reported 3%. The low rates of at-
trition in Boneti 2011 and Gerber 2009 were unlikely to have af-
fected their results and theywere classified at low risk of bias. It was
impossible to determine if the remaining studies had any missing
outcome measures (Adam 2014; Burdge 2013; Horiguchi 2001;
Kim 2010; Oura 1994; Poruk 2015; Sakurai 2013; Shi 2012).
These studies and Stanec 2014 were considered to have unclear
risk of bias.
Selective reporting
Ten of the eleven studies (Adam 2014; Boneti 2011; Burdge 2013;
Gerber 2009; Horiguchi 2001; Kim 2010; Poruk 2015; Sakurai
2013; Shi 2012; Stanec 2014) appeared to be free from selec-
tive outcome and analysis reporting, because the defined statistical
methods and outcomes in the methods section of the study were
employed and reported in the results section.
Other potential sources of bias
We did not identify any other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparison Nipple-
sparing mastectomy for breast cancer treatment; Summary of
findings 2Nipple-sparingmastectomy for breast cancer treatment
The 11 cohort studies, involving 13 treatment comparisons, en-
rolled 6502 participants. Four studies included participants who
underwent either nipple-sparingmastectomy (NSM) or skin-spar-
ing mastectomy (SSM) (Boneti 2011; Burdge 2013; Poruk 2015;
Stanec 2014), five studies included participants who underwent ei-
ther NSM or modified radical mastectomy (MRM) (Adam 2014;
Horiguchi 2001; Oura 1994; Sakurai 2013; Shi 2012) and two
studies involved three treatment comparisons, that is, NSM, SSM
andMRM, and therefore these latter two studies contributed data
for the analysis related to NSM versus SSM, and NSM versus
MRM (Gerber 2009; Kim 2010).
We tried to analyse the outcomes of overall survival and local
recurrence in two different comparisons: NSM versus SSM, and
NSM versus MRM. When this was not possible (e.g. for adverse
effects), we drew the comparison betweenNSM versus other types
of mastectomy (i.e. SSM or MRM, or both).
Formost studies, we could not calculate theHRsbecause outcomes
were not reported in sufficient detail. Many studies only reported
outcomes at the end of follow-up, rather than at specific time
points.
It was not possible to stratify the analyses for participants with
DCIS and those with invasive breast cancer, as had originally been
planned, because insufficient data were available.
Overall survival
Overall survival was evaluated in four of the 11 studies (Adam
2014; Kim 2010; Poruk 2015; Sakurai 2013).
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Nipple-sparing mastectomy versus skin-sparing mastectomy
Two studies involving 781 participants evaluated overall survival
for NSMversus SSM (Kim 2010; Poruk 2015), both of which had
adjusted for some confounders including age and tumour stage.
The HR was 0.70 (95% CI 0.28 to 1.72; 2 studies; 781 partici-
pants; Analysis 1.1; Figure 3) with no heterogeneity across studies
(I2 = 0%; P =0.65). The confidence interval is too wide to draw
any conclusions, and indeed crossed the specified non-inferiority
bound of 1.13. We downgraded the evidence for this outcome
from low to very lowquality due to imprecision, as further research
is very likely to have an important impact on our confidence in
the estimate of effect and may change the estimate.
Figure 3. Forest plot of comparison: 1 Overall survival, outcome: 1.1 NSM vs SSM - overall survival.
Nipple-sparing mastectomy versus modified radical
mastectomy
Two studies involving 1202 participants evaluated overall survival
for NSM versus MRM (Adam 2014; Sakurai 2013). Adam 2014
matched participants for age and tumour stage, but the larger
study, Sakurai 2013 did not adjust for confounding. The HR was
0.72 (95% CI 0.46 to 1.13; 2 studies, 1202 participants; Analysis
1.2; Figure 4) with no heterogeneity (I2 = 0%, P = 0.41). Although
the confidence interval did not cross the specified non-inferiority
bound of 1.13, we were unable to conclude non-inferiority be-
cause of the high risk of confounding. We downgraded the qual-
ity of evidence from low to very low due to the risk of bias and
imprecision.
Figure 4. Forest plot of comparison: 1 Overall survival, outcome: 1.2 NSM vs MRM - overall survival.
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Local recurrence
Eleven studies with 13 treatment comparisons described local re-
currence (Adam 2014; Boneti 2011; Burdge 2013; Gerber 2009;
Horiguchi 2001; Poruk 2015; Kim 2010; Oura 1994; Sakurai
2013; Shi 2012; Stanec 2014).
In total, there were 144 events in 2105womenwhohad undergone
NSM. The recurrent events occurred in 38 out of 118 (32.2%)
women in the nipple or areola, or both, 80 out of 118 (67.8%)
women in the mastectomy flap or regional lymph nodes while the
location was not described in 26 participants.
Two studies involving 1303 participants evaluated the HR for
local recurrence for NSM versus MRM (Adam 2014; Horiguchi
2001). One study matched participants for age and tumour stage
(Adam 2014), and the other adjusted for age, lymph node status
and oestrogen receptor status. The HR was 0.28 (95% CI 0.12 to
0.68, P = 0.005; 2 studies, 1303 participants; Analysis 2.1; Figure
5) with no heterogeneity (I2 = 0%, P= 0.97). However we were
unable to drawfirm conclusions because of the high risk of residual
confounding. We graded the quality of the evidence as very low
due to the risk of bias.
Figure 5. Forest plot of comparison: 2 Local recurrence, outcome: 2.1 NSM vs MRM - local recurrence.
Adverse events
We evaluated overall complications for two studies involving 1067
participants (Sakurai 2013; Shi 2012). Neither study made any
adjustment for confounding. The RR was 0.10 (95% CI 0.01 to
0.82, P = 0.03; 2 studies, 1067 participants; Analysis 3.1) with
significant heterogeneity (I2 = 85%; P = 0.01). We downgraded
the quality of evidence from low to very low due to inconsistency
(i.e. the magnitude of effects across the studies).
Local surgical complications
Explantation of implant/expander
Two studies reported on explantation of the implant/expander
(Boneti 2011; Burdge 2013). Burdge 2013 described the neces-
sity of implant removal in 5% of the participants (3 out of 60
participants) and Boneti 2011 described the necessity of implant
removal for 1% of participants (2 out of 281 in NSM group and
3 out of 227 in the SSM group).
In terms of capsular contracture, three studies described an inci-
dence of 3.1% (9 out of 293 participants; Boneti 2011),10% (6
out of 60 participants; Burdge 2013) and 15% (22 out of 145
participants; Stanec 2014).
Hematoma
Two studies evaluated hematomas (Shi 2012; Stanec 2014). Shi
2012 reported that 2 out of 35 participants had a hematoma or
infection in the NSM group while 5 out of 100 participants had
a hematoma (two participants) or infection (three participants) in
the MRM group. Stanec 2014 reported that 9 out of 252 partic-
ipants had a hematoma in the NSM group while 3 out of 109
participants had a hematoma in the SSM group.
Seroma
Two studies evaluated seromas (Shi 2012; Stanec 2014). Shi 2012
described an incidence of 2.9% (one participant) in the NSM
group versus 14% (14 participants) in theMRM group (P = 0.13).
Stanec 2014 described seroma of the donor site and axilla as a
frequent postoperative complication with 25.6% of participants
(108/361) being treated with aspirative punction in the NSM and
SSM groups.
Rehospitalization/re-exploration
Boneti 2011 described that 0.7% (2 out of 281 breasts) in the
NSM group versus 0.4% (1 out of 227 breasts) in the SSM group
required further exploration for postoperative bleeding. Stanec
2014 described that 1.1% of participants (4 out of 361) needed
further exploration for the drainage of breast abscesses.
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Skin necrosis (nipple, areola or flap necrosis)
Four studies described skin necrosis (Kim 2010; Sakurai 2013; Shi
2012; Stanec 2014). The RR was 4.22 (95% CI 0.59 to 30.03, 4
studies, P = 0.15; 1948 participants; Analysis 3.2; Figure 6) with
significant heterogeneity (I2 = 79%; P = 0.008). We downgraded
the quality of evidence from low to very low due to a wide confi-
dence interval.
Figure 6. Forest plot of comparison: 3 Adverse events, outcome: 3.2 Skin necrosis.
Skin necrosis with revision surgery
Only two studies described this outcome (Boneti 2011; Stanec
2014). Boneti 2011 showed 0.9% (4 out of 404) of participants
had nipple necrosis with revision surgery and Stanec 2014 de-
scribed 3.6% (13 out of 361) of participants needing further ex-
ploration.
Infection
Two studies involving 496 participants evaluated infections fol-
lowing NSM versus other types of mastectomy (Shi 2012; Stanec
2014). Neither study made any adjustment for confounding. The
RR was 0.95 (95% CI 0.44 to 2.09, P = 0.91, 2 studies; 496 par-
ticipants; Analysis 3.3) with no significant heterogeneity (I2 = 0%;
P = 0.39).
Due to a lack of data, it was not possible to perform subgroup
analysis or analyse thromboembolic events as proposed in the pro-
tocol.
Cosmetic results
Five studies performed an evaluation of the aesthetic outcome after
NSM (Boneti 2011; Burdge 2013; Gerber 2009; Shi 2012; Stanec
2014). Boneti 2011 and Burdge 2013 asked the participants to
rate their cosmetic result on a scale from 0 to 10 (with 10 being
the most favourable outcome). In Boneti 2011, the NSM group
gave a mean score of 9.2 versus 8.3 in the SSM group (P = 0.04).
In Burdge 2013, the average rating was 8 by the participants and
9 by the doctors for both groups in total.
In three studies, cosmesis was assessed through personal opinion
and the evaluation was either excellent, good, average or poor
(Gerber 2009; Shi 2012; Stanec 2014).
Stanec 2014 described the aesthetic outcome by the type of pri-
mary reconstruction (that is, latissimus dorsal, implant and deep
inferior epigastric perforators (DIEP)). The best results were with
autologous reconstruction with almost 90% of participants having
excellent or good evaluations compared to almost 70% of partici-
pants with implants. Unsatisfactory reconstruction was higher for
participants who had implants (18.6%) compared to participants
who had autologous reconstruction (7%).
Gerber 2009 described excellent and/or good results for almost
98% of the SSMgroup and 100% for theNSMgroup (P = 0.004).
After 59 months of follow-up, satisfaction (excellent and/or good)
decreased to 88% in the SSM group and 96% in the NSM group
(P = 0.025).
Shi 2012 asked the participants if they were satisfied with the local
aesthetic (yes or no). The participants in the NSM group who
received breast reconstruction felt more satisfied with the resulting
aesthetic appearance (34 out of 35 participants) than those in the
MRM group (20 out of 100 participants, P < 0.001).
Quality of life
Only one study reported this outcome. Shi 2012 used a psycho-
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logical questionnaire and the NSM group had higher levels of self-
confidence (33 out of 35 versus 30 out of 100 participants, P <
0.001), social activity (35 out of 35 versus 60 out of 100 partici-
pants, P < 0.001) and sexual activity (31 out of 35 versus 82 out
of 100 participants, P = 0.52) compared to the MRM group.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Nipple-sparing mastectomy for breast cancer treatment
Patient or population: women with breast cancer
Setting: breast cancer therapy centres
Intervention: nipple-sparing mastectomy
Comparison: skin-sparing mastectomy
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with other types of
mastectomies
Risk with nipple-spar-
ing mastectomy
Overall survival Study populat ion HR 0.70
(0.28 to 1.72)
781
(2 observat ional stud-
ies)
⊕©©©
VERY LOW 1
928 per 1000 841 per 1000
(521 to 989)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io; HR: hazard rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1We downgraded the quality of evidence due to: (a) risk of bias of included studies: non-randomised studies with low quality,
and imprecision: wide conf idence intervals that crossed null ef fect and comprised both direct ions of ef fect
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D I S C U S S I O N
Summary of main results
In general the results were inconclusive because none of the in-
cluded studies had used appropriate methods to deal with con-
founding. In particular, the modified radical mastectomy (MRM)
and skin-sparing mastectomy (SSM) groups tended to have par-
ticipants with more advanced disease than the nipple-sparing mas-
tectomy (NSM) group, and the use of radiotherapy tended to be
different in the different treatment groups. Currently, the indica-
tions for postmastectomy radiation have been extended and this
will probably have an impact on the results in future studies.
Overall survival
The results of this review were inconclusive as to whether there
was a difference in overall survival between NSM and other types
of mastectomy (SSM andMRM) due to a lack of studies reporting
survival outcomes in sufficient detail to extract hazard ratios, and
the high risk of confounding.
Evidence from two studies involving 781 people contributed data
to the overall survival outcome for NSM compared to SSM. The
results were inconclusive because the confidence interval was wide.
Only one of these studies had more than five years of follow-up
(Kim 2010), the other had a mean follow-up of about 25 months
(Poruk 2015).
Evidence from two studies involving 1202 people contributed data
to the overall survival outcome for NSM compared to MRM. The
confidence interval did not cross the non-inferiority bound, but
we were unable to draw any conclusions because of the high risk
of residual confounding.
Local recurrence
For local recurrence, we could extract hazard ratios for only two
studies comparing NSM to MRM, involving 1303 participants.
The confidence interval indicated a lower risk of local recurrence
in the NSM group, but we were unable to draw any conclusions
due to the high likelihood of residual confounding due to lack of
adjustment for tumour stage and radiotherapy.
Adam 2014 matched the participants assigned to each group tak-
ing into account the tumour stage. However, Horiguchi 2001
seemed to have more initial tumours (Stages 0 and 1) in the NSM
group (83 out of 123 participants; 67.5%) than in the MRM
group (277 out of 910 participants; 30.4%) and this imbalance
may have influenced the results.
Only 7.9% (103 out of 1303 participants) received radiotherapy:
7.2% (81 out of 1113 participants) in theMRMgroup and 11.6%
(22 out of 190 participants) in the NSM group. No one received
this treatment in Horiguchi 2001, probably because during that
period the indication for radiotherapy treatment was more lim-
ited. Probably more patients would now receive post-mastectomy
radiotherapy, which would have an impact on the local recurrence
rate.
Adverse events
Again, we could not draw any firm conclusions because of the
high risk of confounding. There seemed to be evidence that the
global rate of complications was lower in the NSM group. The
frequency of this outcome was 0.85% versus 18.4% for NSM and
other types of mastectomy respectively. This was lower than in the
published meta-analysis of Endara 2013, which evaluated 6615
womenundergoingNSM for therapeutic or prophylactic purposes
and observed an incidence of 22% for overall complications. There
was no evidence that infection differed between treatment groups
in this review. One possible reason for the lower frequency in this
Cochrane review is due to the presence of retrospective cohort
studies, where the reporting of medical data may be flawed.
Strengths of this systematic review
Strengths of this systematic review include the following.
• A sensitive search strategy was carried out for all electronic
databases (so as to avoid missing relevant studies). In addition, a
manual search was made of reference lists of relevant studies and
we screened clinical trials registries
• We applied a rigorous method recommended by Cochrane
(Higgins 2011b) when conducting the review.
• The methodological quality of observational studies
included was evaluated and considered in the presentation of
findings. We also evaluated the quality of evidence through an
appropriate tool (GRADE).
Main limitations
The main limitations of this systematic review are a result of the
limited strength of the evidence due to the methodological defi-
ciencies of the existing studies.
• The evidence in this review came from observational studies
(mostly retrospective and low methodological quality), subject to
important biases which increased the uncertainty of the results
and limited the quality of existing evidence.
• It was not possible to calculate the hazard ratio for the
assessment of survival data for all studies because many studies
did not report time-to-event analyses in sufficient detail.
• Inability to perform the subgroup analyses initially
proposed in the published protocol. The proposed analyses
included: presence or absence of adjuvant treatment, participant
age, surgical technique performed, and tumour staging according
to the TNM system.
• This was a systematic review that used aggregated data (in
which the subject of analysis was the study), and not a meta-
analysis of individual data (in which the subject of analysis is the
person or the participant). Therefore, only data published or
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provided subsequently by the authors of the studies were
available.
Overall completeness and applicability of
evidence
In this systematic review, the evidence was incomplete due to a lack
of good-quality studies in this area which have used appropriate
methods to adjust for confounding. Additional research is there-
fore likely to have an important impact on the estimated effect.
Decisions regarding choice of surgical method should be made
jointly by the surgeon and woman after extensive information on
the risks and benefits is provided.
Quality of the evidence
See the ’Summary of findings’ tables: Summary of findings for the
main comparison; Summary of findings 2.
Potential biases in the review process
This systematic review has several strengths. We asked a specific
clinical question and the search strategy was comprehensive. We
included publications of all relevant studies irrespective of lan-
guage. Finally, we rigorously applied the GRADE criteria for each
of the relevant outcomes (Guyatt 2008)
There were several potential biases in the review process. We made
efforts to limit the bias in several ways: two review authors assessed
the eligibility for inclusion and independently assessed the risks of
bias. Although the review authors’ views varied, we decided to ac-
cept the final conclusions after extensive discussion and reaching a
consensus. Carrying out reviews, however, may require a number
of subjective judgements, and it is possible that a different review
team may have reached different decisions regarding the assess-
ments of eligibility and risks of bias. Feedback from readers will
serve to improve the next review update.
Agreements and disagreements with other
studies or reviews
We found ameta-analysis by de La Cruz 2015 addressing the same
clinical question as our Cochrane review. The de La Cruz 2015
meta-analysis included eight studies and the authors found no
difference between NSM and MRM/SSM: 3.4 % risk difference
in overall survival (P = 0.073), 9.6 % risk difference in disease-free
survival (P = 0.056), and a 0.4 % risk difference in local recurrence
(P = 0.567). These results are quite similar to our results and it
was not possible to conclude that NSM was not inferior to other
surgeries, because of the limited methodological quality and risk
of bias of the included studies.
The most important methodological differences between the
meta-analysis by de La Cruz 2015 and our review are:
• de La Cruz 2015 limited their search to Pubmed, Scopus
and Google Scholar, included only studies in English, and used
outcome (survival) in the search strategy. We included additional
searches in Embase and CENTRAL databases, we did not use a
language limit and did not specify any outcomes in the search
strategy. Limiting the search string by outcome enhances
specificity but reduces sensitivity which is not recommended in
the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011b).
• de La Cruz 2015 used the risk difference to compare time-
to-event outcomes between intervention groups. We performed
these analyses using hazard ratios (which was more appropriate).
Moreover, we split the analysis into two subgroups NSM versus
SSM and NSM versus MRM because we considered SSM and
MRM to be different control groups, which could influence the
results.
• de La Cruz 2015 did not assess the methodological quality
and risk of bias of the included studies nor the overall quality of
the evidence for each outcome. We did both assessments in
accordance with the Cochrane Handbook for Systematic Reviews of
Interventions using the ’Risk of bias table’ and GRADE
approach, respectively (Higgins 2011b).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
• The evidence was inconclusive regarding the difference in
overall survival and local recurrence between the nipple-sparing
mastectomy (NSM) group and other types of mastectomy
(modified radical (MRM) and skin-sparing mastectomy (SSM)).
Additional research is likely to have an important impact on the
estimated effect.
• No firm recommendations can be made to health
professionals or patients and decisions should be made jointly
after extensive discussion about the risks and benefits before
performing a NSM.
• Health Managers should not adopt this as a health policy
for the time being, but it could be adopted in some special cases.
Implications for research
• This review showed the shortage of well-conducted studies
to evaluate the efficacy and safety of NSM in people with
invasive breast cancer and ductal carcinoma in situ.
• Well-designed cohort studies are still needed.
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• For planning and development of these studies, some
suggestions are:
◦ Use the CONSORT Statement to guide study
methods (Schulz 2010)
◦ Describe and adjust for all potential confounders
◦ Use standardised criteria defining endpoints, quality of
life and follow-up
◦ Longer follow-up is needed to allow observation of
long-term outcomes.
◦ Studies need to adjust appropriately for follow-up
time in the analysis of outcomes by using survival analysis
methods or person-years of follow-up as the denominator for the
incidence rates for events of interest
A C K N OW L E D G E M E N T S
The authors wish to thank all themembers of the Cochrane Breast
Cancer Group for their hard work in editing and reviewing the
review protocol. Also, we thank the Cochrane Handbook Study
Group from the BrazilianCochraneCenter for themethodological
support and the Japan Cochrane Center for language support.
The authors wish to thank Prof. Dr Zdenko Stanec and Zeljka
Roje from Department for Plastic, Reconstructive and Aesthetic
Surgery, University Hospital Dubrava, Zagreb, Croatia for their
data support.
R E F E R E N C E S
References to studies included in this review
Adam 2014 {published data only}
Adam H, Bygdeson M, de Boniface J. The oncological
safety of nipple-sparing mastectomy - a Swedish matched
cohort study. European Journal of Surgical Oncology 2014;
40(10):1209–15. [4477992]
Boneti 2011 {published data only}
Boneti C, Yuen J, Santiago C, Diaz Z, Robertson Y,
Korourian S, et al. Oncologic safety of nipple skin-
sparing or total skin-sparing mastectomies with immediate
reconstruction. Journal of American College of Surgeons
2011;212(4):686–93. [4477994]
Burdge 2013 {published data only}
Burdge EC, Yuen J, Hardee M, Gadgil PV, Das C, Henry-
Tillman R, et al. Nipple skin-sparing mastectomy is feasible
for advanced disease. Annals of Surgical Oncology 2013;20
(10):3294–302. [4477996]
Gerber 2009 {published data only}
Gerber B, Krause A, Dieterich M, Kundt G, Reimer T.
The oncological safety of skin sparing mastectomy with
conservation of the nipple-areola complex and autologous
reconstruction: an extended follow-up study. Annals of
Surgery 2009;249(3):461–8. [4477998]
Horiguchi 2001 {published data only}
Horiguchi J, Iino JHY, Takei H, Koibuchi Y, Iijima K, Ikeda
F, et al. A comparative study of subcutaneous mastectomy
with radical mastectomy. Anticancer Research 2001;21(4B):
2963–7. [4478000]
Kim 2010 {published data only}
Kim HJ, Park EH, Lim WS, Seo JY, Koh BS, Lee
TJ, et al. Nipple areola skin-sparing mastectomy with
immediate transverse rectus abdominis musculocutaneous
flap reconstruction is an oncologically safe procedure: a
single center study. Annals of Surgery 2010;251(3):493–8.
[4478002]
Oura 1994 {published data only}
Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T,
Naito Y, et al. Nipple-preserved mastectomy (Glt + AX) as
a standard operation for p-stage 1, 2 breast cancer. Nihon
Geka Gakkai Zasshi 1994;95(12):887–92. [4478004]
Poruk 2015 {published data only}
Poruk KE, Ying J, Chidester JR, Olson JR, Matsen CB,
Neumayer L, et al. Breast cancer recurrence after nipple-
sparing mastectomy: one institution’s experience. American
Journal of Surgery 2015;209(1):212–7. [4478006; DOI:
10.1016]
Sakurai 2013 {published data only}
Sakurai T, Zhang N, Suzuma T, Umemura T, Yoshimura
G, Sakurai T, et al. Long-term follow-up of nipple-sparing
mastectomy without radiotherapy: a single center study at
a Japanese institution. Medical Oncology 2013;30(1):481.
[4478008]
Shi 2012 {published data only}
Shi A, Wu D, Li X, Zhang S, Li S, Xu H, et al.
Subcutaneous nipple-sparing mastectomy and immediate
breast reconstruction. Breast Care 2012;7(2):131–6.
[4478010]
Stanec 2014 {published data only}
Stanec Z, ic R, Budi S, Stanec S, Milanovi R, Vlaj
i Z, et al. Skin and nipple-areola complex sparing
mastectomy in breast cancer patients: 15-year experience.
Annals of Plastic Surgery 2014;73(5):485–91. [4478012;
DOI: 10.1097]
References to studies excluded from this review
24Nipple- and areola-sparing mastectomy for the treatment of breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Algaithy 2012 {published data only}
Algaithy ZK, Petit JY, Lohsiriwat V, Maisonneuve P, Rey
PC, Baros N, et al. Nipple sparing mastectomy: can we
predict the factors predisposing to necrosis?. European
Journal of Surgical Oncology 2012;38(2):125–9. [4478014]
Alperovich 2014 {published data only}
Alperovich M, Choi M, Frey JD, Lee ZH, Levine JP,
Saadeh PB, et al. Nipple-sparing mastectomy in patients
with prior breast irradiation: are patients at higher risk for
reconstructive complications?. Plastic and Reconstructive
Surgery 2014;134(2):202–6e. [4478016]
Babiera 2010 {published data only}
Babiera G, Simmons R. Nipple-areolar complex-sparing
mastectomy: feasibility, patient selection, and technique.
Annals of Surgical Oncology 2010;17(3):245–8. [4478018]
Benediktsson 2008 {published data only}
Benediktsson KP, Perbeck L. Survival in breast cancer after
nipple-sparing subcutaneous mastectomy and immediate
reconstruction with implants: a prospective trial with 13
years median follow-up in 216 patients. European Journal of
Surgical Oncology 2008;34(2):143–8. [4478020]
Caruso 2006 {published data only}
Caruso F, Ferrara M, Castiglione G, Trombetta G, De
Meo L, Catanuto G, et al. Nipple sparing subcutaneous
mastectomy: sixty-six months follow-up. European Journal
of Surgical Oncology 2006;32(9):937–40. [4478022]
Chattopadhyay 2014 {published data only}
Chattopadhyay D, Gupta S, Jash PK, MurmuMB, Gupta S.
Skin sparing mastectomy with preservation of nipple areola
complex and immediate breast reconstruction in patients
with breast cancer: a single centre prospective study. Plastic
Surgery International 2014;2014:589068. [4478024]
Crowe 2008 {published data only}
Crowe JP, Patrick RJ, Yetman RJ, Djohan R. Nipple-sparing
mastectomy update: one hundred forty-nine procedures
and clinical outcomes. Archives of Surgery 2008;143(11):
1106–10. [4478026]
de Alcantara Filho 2011 {published data only}
de Alcantara Filho P, Capko D, Barry JM, Morrow M,
Pusic A, Sacchini VS. Nipple-sparing mastectomy for breast
cancer and risk-reducing surgery: the Memorial Sloan-
Kettering Cancer Center experience. Annals of Surgical
Oncology 2011;18(11):3117–22. [4478028]
Eisenberg 2014 {published data only}
Eisenberg RE, Chan JS, Swistel AJ, Hoda SA. Pathological
evaluation of nipple-sparing mastectomies with emphasis
on occult nipple involvement: the Weill-Cornell experience
with 325 cases. Breast Journal 2014;20(1):15–21.
[4478030]
Fortunato 2013 {published data only}
Fortunato L, Loreti A, Andrich R, Costarelli L, Amini
M, Farina M, et al. When mastectomy is needed: is the
nipple-sparing procedure a new standard with very few
contraindications?. Journal of Surgical Oncology 2013;108
(4):207–12. [4478032]
Garcia-Etienne 2009 {published data only}
Garcia-Etienne CA, Cody HS 3rd, Disa JJ, Cordeiro P,
Sacchini V. Nipple-sparing mastectomy: initial experience
at the Memorial Sloan-Kettering Cancer Center and a
comprehensive review of literature. Breast Journal 2009;5
(4):440–9. [4478034]
Garwood 2009 {published data only}
Garwood ER, Moore D, Ewing C, Hwang ES, Alvarado
M, Foster RD, et al. Total skin-sparing mastectomy:
complications and local recurrence rates in 2 cohorts of
patients. Annals of Surgery 2009;249(1):26–32. [4478036]
Jensen 2011 {published data only}
Jensen JA, Orringer JS, Giuliano AE. Nipple-sparing
mastectomy in 99 patients with a mean follow-up of 5
years. Annals of Surgical Oncology 2011;18(6):1665–70.
[4478038]
Leclère 2014 {published data only}
Leclère FM, Panet-Spallina J, Kolb F, Garbay JR, Mazouni
C, Leduey A, et al. Nipple-sparing mastectomy and
immediate reconstruction in ductal carcinoma in situ: a
critical assessment with 41 patients. Aesthetic Plastic Surgery
2014;38(2):338–43. [4478040]
Lohsiriwat 2013 {published data only}
Lohsiriwat V, Rotmensz N, Botteri E, Intra M, Veronesi P,
Martella S, et al. Do clinicopathological features of the
cancer patient relate with nipple areolar complex necrosis
in nipple-sparing mastectomy?. Annals of Surgical Oncology
2013;20(3):990–6. [4478042]
Maxwell 2011 {published data only}
Maxwell GP, Storm-Dickerson T, Whitworth P, Rubano
C, Gabriel A. Advances in nipple-sparing mastectomy:
oncological safety and incision selection. Aesthetic Surgery
Journal 2011;31(3):310–9. [4478044]
Missana 2007 {published data only}
Missana MC, Germain MA, Spielman M, Mathieu
MC, Rose M, Dunant A, et al. Nipple areola complex
conservation in immediate breast reconstruction:
prospective study of 66 cases. Journal de Chirurgie 2007;
144(6):516–21. [4478046]
Munhoz 2013 {published data only}
Munhoz AM, Aldrighi CM,Montag E, Arruda EG, Aldrighi
JM, Gemperli R, et al. Clinical outcomes following nipple-
areola-sparing mastectomy with immediate implant-based
breast reconstruction: a 12-year experience with an analysis
of patient and breast-related factors for complications.
Breast Cancer Research and Treatment 2013;140(3):545–55.
[4478048]
Nava 2012 {published data only}
Nava MB, Ottolenghi J, Pennati A, Spano A, Bruno N,
Catanuto G, et al. Skin/nipple sparing mastectomies and
implant-based breast reconstruction in patients with large
and ptotic breast: oncological and reconstructive results.
Breast 2012;21(3):267–71. [4478050]
Ohno 2013 {published data only}
Ohno Y, Noguchi M, Yokoi-Noguchi M, Nakano Y,
Shimada K, Yamamoto Y, et al. Nipple- or skin-sparing
25Nipple- and areola-sparing mastectomy for the treatment of breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
mastectomy and immediate breast reconstruction by the
“moving window” operation. Breast Cancer 2013;20(1):
54–61. [4478052]
Paepke 2009 {published data only}
Paepke S, Schmid R, Fleckner S, Paepke D, Niemeyer
M, Schmalfeldt B, et al. Subcutaneous mastectomy with
conservation of the nipple-areola skin: broadening the
indications. Annals of Surgery 2009;250(2):288–92.
[4478054]
Peled 2014 {published data only}
Peled AW, Foster RD, Ligh C, Esserman LJ, Fowble B,
Sbitany H. Impact of total skin-sparing mastectomy incision
type on reconstructive complications following radiation
therapy. Plastic and Reconstructive Surgery 2014;134(2):
169–75. [4478056]
Petit 2003 {published data only}
Petit JY, Veronesi U, Orecchia R, Rey P, Didier F, Giraldo
A, et al. The nipple-sparing mastectomy: early results of
a feasibility study of a new application of perioperative
radiotherapy (ELIOT) in the treatment of breast cancer
when mastectomy is indicated. Tumori 2003;89(3):288–91.
[4478058]
Petit 2006 {published data only}
Petit JY, Veronesi U, Orecchia R, Luini A, Rey P, Intra M,
et al. Nipple-sparing mastectomy in association with intra
operative radiotherapy (ELIOT): a new type of mastectomy
for breast cancer treatment. Breast Cancer Research and
Treatment 2006;96(1):47–51. [4478060]
Petit 2009b {published data only}
Petit JY, Veronesi U, Orecchia R, Rey P, Martella S, Didier
F, et al. Nipple sparing mastectomy with nipple areola
intraoperative radiotherapy: one thousand and one cases of
a five years experience at the European Institute of Oncology
of Milan (EIO). Breast Cancer Research and Treatment 2009;
117(2):333–8. [4478062]
Petit 2012 {published data only}
Petit JY, Veronesi U, Orecchia R, Curigliano G, Rey PC,
Botteri E, et al. Risk factors associated with recurrence after
nipple-sparing mastectomy for invasive and intraepithelial
neoplasia. Annals of Oncology 2012;23(8):2053–8.
[4478064]
Rache Simmons 2004 {published data only}
Simmons RM, Hollenbeck ST, Latrenta GS. Two-year
follow-up of areola-sparing mastectomy with immediate
reconstruction. American Journal of Surgery 2004;188(4):
403–6. [4478066]
Radovanovic 2010 {published data only}
Radovanovic Z, Radovanovic D, Golubovic A, Ivkovic-
Kapicl T, Bokorov B, Mandic A. Early complications
after nipple-sparing mastectomy and immediate breast
reconstruction with silicone prosthesis: results of 214
procedures. Scandinavian Journal of Surgery 2010;99(3):
115–8. [4478068]
Reefy 2010 {published data only}
Reefy S, Patani N, Anderson A, Burgoyne G, Osman H,
Mokbel K. Oncological outcome and patient satisfaction
with skin-sparing mastectomy and immediate breast
reconstruction: a prospective observational study. BMC
Cancer 2010;29(10):171. [4478070]
Regolo 2008 {published data only}
Regolo L, Ballardini B, Gallarotti E, Scoccia E, Zanini V.
Nipple sparing mastectomy: an innovative skin incision
for an alternative approach. Breast 2008;17(1):8–11.
[4478072]
Rusgby 2010 {published data only}
Rusby JE, Gui G. Nipple-sparing mastectomy in women
with large or ptotic breasts. Journal of Plastic, Reconstructive
and Anaesthetic Surgery 2010;63(10):754–5. [4478074]
Sachinni 2006 {published data only}
Sacchini V, Pinotti JA, Barros AC, Luini A, Pluchinotta
A, Pinotti M, et al. Nipple-sparing mastectomy for breast
cancer and risk reduction: oncologic or technical problem?
. Journal of the American College of Surgeons 2006;203(5):
704–14. [4478076]
Salgarello 2010 {published data only}
Salgarello M, Visconti G, Barone-Adesi L. Nipple-sparing
mastectomy with immediate implant reconstruction:
cosmetic outcomes and technical refinements. Plastic and
Reconstructive Surgery 2010;126(5):1460–71. [4478078]
Schneider 2012 {published data only}
Schneider LF, Chen CM, Stolier AJ, Shapiro RL, Ahn CY,
Allen RJ. Nipple-sparing mastectomy and immediate free-
flap reconstruction in the large ptotic breast. Annals of
Plastic Surgery 2012;69(4):425–8. [4478080]
Sookhan 2008 {published data only}
Sookhan N, Boughey JC, Walsh MF, Degnim AC. Nipple-
sparing mastectomy - initial experience at a tertiary center.
American Journal of Surgery 2008;196(4):575–7. [4478082]
Spear 2011 {published data only}
Spear SL, Willey SC, Feldman ED, Cocilovo C, Sidawy M,
Al-Attar A, Hannan C, et al. Nipple-sparing mastectomy
for prophylactic and therapeutic indications. Plastic and
Reconstructive Surgery 2011;128(5):1005–14. [4478084]
Stolier 2008 {published data only}
Stolier AJ, Sullivan SK, Dellacroce FJ. Technical
considerations in nipple-sparing mastectomy: 82
consecutive cases without necrosis. Annals of Surgical
Oncology 2008;15(5):1341–7. [4478086]
Tancredi 2013 {published data only}
Harness JK, Vetter TS, Salibian AH. Areola and nipple-
areola-sparing mastectomy for breast cancer treatment
and risk reduction: report of an initial experience in a
community hospital setting. Annals of Surgical Oncology
2011;18(4):917–22. [4478088]
∗ Tancredi A, Ciuffreda L, Petito L, Natale F, Murgo R.
Nipple-areola-complex sparing mastectomy: five years of
experience in a single centre. Updates in Surgery 2013;65
(4):289–94. [4478089]
Voltura 2008 {published data only}
Voltura AM, Tsangaris TN, Rosson GD, Jacobs LK,
Flores JI, Singh NK, et al. Nipple-sparing mastectomy:
26Nipple- and areola-sparing mastectomy for the treatment of breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
critical assessment of 51 procedures and implications for
selection criteria. Annals of Surgical Oncology 2008;15(12):
3396–401. [4478091]
Wagner 2012 {published data only}
Wagner JL, Fearmonti R, Hunt KK, Hwang RF, Meric-
Bernstam F, Kuerer HM, et al. Prospective evaluation
of the nipple-areola complex sparing mastectomy for risk
reduction and for early-stage breast cancer. Annals of
Surgical Oncology 2012;19(4):1137–44. [4478093]
Wijayanayagam 2008 {published data only}
Wijayanayagam A, Kumar AS, Foster RD, Esserman LJ.
Optimizing the total skin-sparing mastectomy. Archives of
Surgery 2008;143(1):38–45. [4478095]
References to studies awaiting assessment
Seki 2015 {published data only}
Shimo 2015 {published data only}
Additional references
Andersen 1979
Andersen JA, Pallesen RM. Spread to the nipple and areola
in carcinoma of the breast. Annals of Surgery 1979;189(3):
367–72.
Banerjee 2008
Banerjee A, Gupta S, Bhattacharya N. Preservation of
nipple-areola complex in breast cancer - a clinicopathological
assessment. Journal of Plastic, Reconstructive & Aesthetic
Surgery 2008;61(10):1195–8.
Chung 2008
Chung AP, Sacchini V. Nipple-sparing mastectomy: where
are we now?. Surgical Oncology 2008;17:261–6.
Cochrane EPOC Group 2013
Cochrane Effective Practice and Organisation of Care
(EPOC) Group. Risk of bias. epoc.cochrane.org/
sites/epoc.cochrane.org/files/uploads/Sug-
gested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews.pdf
(accessed 10/10/2013).
de La Cruz 2015
De La Cruz L, Moody AM, Tappy EE, Blankenship SA,
Hecht EM. Overall survival, disease-free survival, local
recurrence, and nipple-areolar recurrence in the setting of
nipple-sparing mastectomy: a meta-analysis and systematic
review. Annals of Surgical Oncology 2015;22(10):3241-9.
[DOI: 10.1245/s10434-015-4739-1]
Deeks 2011
Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9:
Analysing data and undertaking meta-analyses. In: Higgins
JPT, Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Endara 2013
Endara M, Chen D, Verma K, Nahabedian MY, Spear SL.
Breast reconstruction following nipple-sparing mastectomy:
a systematic review of the literature with pooled analysis.
Plastic or Reconstructive Surgery 2013;132(5):1043–54.
Ferlay 2012
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin
DM. GLOBOCAN: Cancer Incidence and Mortality
Worldwide: IARC CancerBase. http://globocan.iarc.fr
2012.
Freeman 1962
Freeman BS. Subcutaneous mastectomy for benign breast
lesions with immediate or delayed prosthetic replacement.
Plastic and Reconstructive Surgery and the Transplantation
Bulletin 1962;30:676–82.
Gentil 1980
Gentil F, Callia W, de Souza e Sá A, Cavalcanti S, Garcia
E, Giannotti Filho O, et al. Mammary carcinoma -
multidisciplinary treatment with bilateral mastectomy and
immediate reconstruction. Journal of Surgical Oncology
1980;14(2):173–93.
Gordis 1996
Gordis L. Epidemiology. Philadelphia: W.B. Saunders,
1996:116–8.
Guyatt 2008
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y,
Alonso-Coello P, et al. GRADE Working Group. GRADE:
an emerging consensus on rating quality of evidence and
strength of recommendations. BMJ 2008;336(7650):
924–6. [DOI: 10.1136]
Hartmann 2001
Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg
CL, Sitta D. Efficacy of bilateral prophylactic mastectomy
in BRCA1 and BRCA2 gene mutation carriers. Journal of
the National Cancer Institute 2001;93:1633–7.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327
(7414):557–60.
Higgins 2011a
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter
8: Assessing risk of bias in included studies. In: Higgins
JPT, Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Higgins 2011b
Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011]. The Cochrane Collaboration, 2011Higgins
JPT, Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Josephson 2000
Josephson U, Wickman M, Sandelin K. Initial experiences
of women from hereditary breast cancer families after
bilateral prophylactic mastectomy: a retrospective study.
European Journal of Surgical Oncology 2000;26:351–6.
27Nipple- and areola-sparing mastectomy for the treatment of breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lagios 1979
Lagios MD, Gates EA, Westdahl PR, Richards V, Alpert BS.
A guide to the frequency of nipple involvement in breast
cancer. A study of 149 consecutive mastectomies using
a serial subgross and correlated radiographic technique.
American Journal of Surgery 1979;138(1):135–42.
Lakhani 2012
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver
MJ. WHO Classification of Tumours of the Breast. 4th
Edition. Vol. 4, IARC Publications, 2012.
Laronga 1999
Laronga C, Kemp B, Johnston D, Robb GL, Singletary
SE. The incidence of occult nipple-areola complex
involvement in breast cancer patients receiving a skin-
sparing mastectomy. Annals of Surgical Oncology 1999;6(6):
609–13.
Loewen 2008
Loewen MJ, Jennings JA, Sherman SR, Slaikeu J, Ebrom
PA, Davis AT, et al. Mammographic distance as a predictor
of nipple-areola complex involvement in breast cancer.
American Journal of Surgery 195;3:391–4.
Lostumbo 2010
Lostumbo L, Carbine NE, Wallace J. Prophylactic
mastectomy for the prevention of breast cancer. Cochrane
Database of Systematic Reviews 2010, Issue 11. [DOI:
10.1002/14651858.CD002748.pub3]
Luttges 1987
Luttges J, Kalbfleisch H, Prinz P. Nipple involvement and
multicentricity in breast cancer. A study on whole organ
sections. Journal of Cancer Research and Clinical Oncology
1987;113(5):481–7.
Menon 1989
Menon RS, Van Geel AN. Cancer of the breast with nipple
involvement. British Journal of Cancer 1989;59(1):81–4.
Morimoto 1985
Morimoto T, Komaki K, Inui K, Umemoto A, Yamamoto
H, Harada K, et al. Involvement of nipple and areola in
early breast cancer. Cancer 1985;55(10):2459–63.
Morrow 2002
Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble
B, Giuliano A, et al. Standard for breast conservation
therapy in the management of invasive breast carcinoma. A
Cancer Journal for Clinicians 2002;52(5):277–300.
NCI 2013
National Cancer Institute. Fact sheet: cancer staging.
www.cancer.gov/cancertopics/factsheet/detection/staging
(accessed 4 January 2013).
Norris 2013
Norris SL, Moher D, Reeves BC, Shea B, Loke Y, Garner S,
et al. Issues relating to selective reporting when including
non-randomized studies in systematic reviews on the effects
of healthcare interventions. Research Synthesis Methods
2013;4(1):36–47.
Parmar 1998
Parmar MKB, Torri V, Stewart L. Extracting summary
statistics to perform meta-analyses of the published literature
for survival endpoints. Statistics in Medicine 1998;17(24):
2815–34.
Parry 1977
Parry RG, Cochran TC, Jr, Wolfort FG. When is there
nipple involvement in carcinoma of the breast?. Plastic and
Reconstructive Surgery 1977;59(4):535–7.
Pennisi 1989
Pennisi VR, Capozzi A. Subcutaneous mastectomy data: a
final statistical analysis of 1500 patients. Aesthetic Plastic
Surgery 1989;13:15–21.
Petit 2009a
Petit JY, Veronesi U, Rey P, Rotmensz N, Botteri E, Rietjens
M, et al. Nipple-sparing mastectomy: risk of nipple-areolar
recurrences in a series of 579 cases. Breast Cancer Research
and Treatment 2009;114(1):97–101.
Quinn 1981
Quinn RH, Barlow JF. Involvement of the nipple and areola
by carcinoma of the breast. Archives of Surgery 1981;116(9):
1139–40.
RevMan 2014 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
RevMan 5 (RevMan 5). Version 5.3. Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Rusby 2008
Rusby JE, Brachtel EF, Othus M, Michaelson JS, Koerner
FC, Smith BL. Development and validation of a model
predictive of occult nipple involvement in women
undergoing mastectomy. British Journal of Surgery 2008;95
(11):1356–61.
Sacchini 2006
Sacchini V, Pinotti JA, Barros AC, Luini A, Pluchinotta
A, Pinotti M, et al. Nipple-sparing mastectomy for breast
cancer and risk reduction: oncologic or technical problem?
. Journal of the American College of Surgeons 2006;203(5):
704–14.
Santini 1989
Santini D, Taffurelli M, Gelli MC, Grassigli A, Giosa F,
Marrano D, et al. Neoplastic involvement of nipple-areolar
complex in invasive breast cancer. American Journal of
Surgery 1989;158(5):399–403.
Schecter 2006
Schecter AK, Freeman MB, Giri D, Sabo E, Weinzweig
J. Applicability of the nipple-areola complex-sparing
mastectomy: a prediction model using mammography
to estimate risk of nipple-areola complex involvement in
breast cancer patients. Annals of Plastic Surgery 2006;56(5):
498–504.
Schulz 2010
Schulz KF, Altman DG, Moher D, for the CONSORT
Group. CONSORT 2010 Statement: updated guidelines
28Nipple- and areola-sparing mastectomy for the treatment of breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
for reporting parallel group randomised trials. Annals of
Internal Medicine 2010;152:Epub 24 March.
Simmons 2002
Simmons RM, Brennan M, Christos P, King V, Osborne M.
Analysis of nipple/areolar involvement with mastectomy:
can the areola be preserved?. Annals of Surgical Oncology
2002;9(2):165–8.
Singletary 2003
Singletary SE, Robb GL. Oncologic safety of skin-sparing
mastectomy. Annals of Surgical Oncology 2003;10(2):95–7.
Smith 1976
Smith J, Payne WS, Carney JA. Involvement of the nipple
and areola in carcinoma of the breast. Surgery, Gynecology
and Obstetrics 1976;143(4):546–8.
Verma 1997
Verma GR, Kumar A, Joshi K. Nipple involvement in
peripheral breast carcinoma: a prospective study. Indian
Journal of Cancer 1997;34(1):1–5.
Veronesi 1990
Veronesi U, Salvadori B, Luini A, Banfi A, Zucali R, Del
Vecchio M, et al. Conservative treatment of early breast
cancer. Long-term results of 1232 cases treated with
quadrantectomy, axillary dissection, and radiotherapy.
Annals of Surgery 1990;211(3):250–9.
Veronesi 2002
Veronesi U, Cascinelli N, Mariani L Greco M, Saccozzi
R, Luini A, et al. Twenty-year follow-up of a randomized
study comparing breast-conserving surgery with radical
mastectomy for early breast cancer. New England Journal of
Medicine 2002;347:1227–32.
Vyas 1998
Vyas JJ, Chinoy RF, Vaidya JS. Prediction of nipple and
areola involvement in breast cancer. European Journal of
Surgical Oncology 1998;24(1):15–6.
Wetheim 1980
Wertheim U, Ozzello L. Neoplastic involvement of nipple
and skin flap in carcinoma of the breast. American Journal
of Surgical Pathology 1980;4(6):543–9.
∗ Indicates the major publication for the study
29Nipple- and areola-sparing mastectomy for the treatment of breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adam 2014
Methods • Retrospective matched cohort study
• Conducted at the Department of Breast Surgery Karolinska University Hospital,
Stockholm, Sweden
• The cases were identified by registry data from the Swedish Breast Cancer Register
- 1:3 to patients operated by conventional mastectomy. Matching variables were age,
tumour stage and year of surgery.
• 270 participants
• Intervention group: 67 NSM
• Control group: 203 MRM randomly selected
• Follow-up was performed during an outpatient clinic visit (medical record)
• The median follow-up time was 36 months (4 to 162 months) for NSM and 35
months for MRM (range 0 to 160 months).
Participants Inclusion criteria
• Breast cancer confirmed by pathological methods
• ALL NSMs performed during 2000 to 2012 were from Karolinska University
Hospital for breast cancer treatment
• The participants selected for the NSM procedure had a tumour of at least 2 cm,
no skin involvement, no pathological nipple discharge and no signs
• Intraoperative biopsies of mammary gland specimens resected from below the
nipple-areola complex (NAC) confirmed that both the NAC and the skin were not
cancerous to perform the NSM procedure.
• The Intervention cases (NSM participants) were from Karolinska University
Hospital and the control group were women with breast cancer operated at any
hospital in the Stockholm and Gotland region by conventional mastectomy without
immediate breast reconstruction
Interventions • Intervention group:
◦ NSM with immediate breast reconstruction
• Control group:
◦ MRM
In addition to surgery, participants in both groups received adjuvant treatment as rec-
ommended by the National Comprehensive Cancer Network (NCCN) guidelines
Outcomes • Primary outcomes
◦ Local recurrence - specified as histologically proven recurrent breast cancer in
the ipsilateral skin, chest wall or the NAC.
• Secondary endpoints were
◦ local recurrence-free survival, calculated from the date of surgery until the
date of diagnosis for a local recurrence
◦ disease-free survival (DFS), calculated from the date of surgery to the first
event of any local, regional or distant recurrence
◦ breast cancer-specific survival, calculated from the date of surgery to death
due to breast cancer, or the date of medical record review
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Adam 2014 (Continued)
◦ overall survival, calculated from the date of surgery to death from any cause,
or to the date of medical record review in all other cases.
Notes There were no NAC recurrences in the study group.
The study author was contacted to provide the absolute number of people alive and local
recurrence
Risk of bias
Bias Authors’ judgement Support for judgement
SelectionBias -Was the allocation sequence
adequately generated?
High risk Retrospective matched cohort
Selection Bias - Was the allocation ade-
quately concealed?
High risk Retrospective matched cohort
Selection Bias - Were baseline characteris-
tics similar?
Unclear risk Tumour stage and age at baseline were sim-
ilar in both groups. Adjuvant chemother-
apy and radiotherapy use were not reported
Selection Bias - Was there adequate adjust-
ment for confounding?
High risk Participants were matched for age, tumour
stage and year of study. No adjustment was
made for adjuvant radiotherapy, surgical
techniques or chemotherapy
Performance/detection bias - Was knowl-
edge of the allocated interventions ade-
quately prevented during the study?
High risk The lack of blinding may have influenced
the results for some outcomes. Time-to-
event outcomes are generally more objec-
tive and therefore less likely to be prone to
bias. Surgical reports, however, could be in-
fluenced by knowledge of the procedure
Attrition bias - Were incomplete outcome
data adequately addressed?
Unclear risk It was not mentioned in the methods sec-
tion
Reporting bias - Were reports of the study
free from selective outcome reporting?
Low risk There was no evidence that outcomes were
selectively reported
Reporting Bias - Were reports of the study
free from selective analysis reporting?
Low risk There was no evidence of selective report-
ing of analysis
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Boneti 2011
Methods • Retrospective cohort
• Conducted at the Division of Breast Surgical Oncology, Department of Surgery,
Winthrop P. Rockefeller Cancer Institute (Boneti, Santiago, Diaz, Robertson,
Westbrook, Henry-Tillman, Klimberg), Division of Plastic Surgery, Department of
Surgery (Yuen), and Department of Pathology (Korourian), University of Arkansas for
Medical Sciences, Little Rock, Arkansas
• 293 participants
• Intervention group: 141 NSM
• Control group: 152 SSM
• The median follow-up was 25 months for NSM group and 38 months for SSM
group
• 1998 to 2010
Participants Inclusion criteria
• Informed consent signed
• Breast cancer confirmed by pathological methods
• The NSM procedure was offered to participants. The participants chose one
surgical approach over the other for aesthetic reasons.
• Intraoperative biopsies of mammary gland specimens resected from below the
NAC confirmed that both the NAC and the skin were not cancerous to perform the
NSM procedure
Exclusion criteria
• Exclusion criteria included locally advanced disease, inflammatory breast cancer,
collagen vascular disease, smoking within the previous 6 months
• Radiation was a relative exclusion (depended on skin radiation damage)
Interventions • Intervention group:
◦ NSM
• Control group:
◦ SSM
• Both groups:
◦ Chemotherapy was recommended for participants when the estimated
benefit of chemotherapy outweighed the risks
◦ participants with original tumours larger than 5 cm, 4 or more positive
lymph nodes, or chest wall invasion diagnosed on the final pathology report were given
5,000 units of external beam conformal radiation to the total skin after all surgery and
systemic therapy were completed
◦ Breast reconstruction was performed either immediately via implant or with
expanders followed by implants.
Outcomes • Local recurrence
• Adverse events
• Cosmetic results
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Boneti 2011 (Continued)
SelectionBias -Was the allocation sequence
adequately generated?
High risk Retrospective cohort study
Selection Bias - Was the allocation ade-
quately concealed?
High risk Retrospective cohort study
Selection Bias - Were baseline characteris-
tics similar?
Unclear risk Mean tumour size and mean baseline age
was similar between intervention groups.
Adjuvant chemotherapy and radiotherapy
use were not reported
Selection Bias - Was there adequate adjust-
ment for confounding?
High risk No adjustmentwasmade for potential con-
founders
Performance/detection bias - Was knowl-
edge of the allocated interventions ade-
quately prevented during the study?
High risk The lack of blinding may have influenced
the results for some outcomes. Time-to-
event outcomes are generally more objec-
tive and therefore less likely to be prone to
bias. Surgical reports, however, could be in-
fluenced by knowledge of the procedure
Attrition bias - Were incomplete outcome
data adequately addressed?
Low risk Missing outcome measures were unlikely
to bias the results. 15 participants were lost
to follow-up within the first 3 months after
the mastectomy operation
Reporting bias - Were reports of the study
free from selective outcome reporting?
Low risk There was no evidence that outcomes were
selectively reported
Reporting Bias - Were reports of the study
free from selective analysis reporting?
Low risk There was no evidence that analyses were
selectively reported
Burdge 2013
Methods • Retrospective cohort
• Conducted at the Division of Breast Surgical Oncology, Winthrop P. Rockefeller
Cancer Institute, University of Arkansas for Medical Sciences, Arkansas Breast Cancer,
New York, NY
• 60 participants
• Intervention group: 39 NSM
• Control Group: 21 SSM
• Follow-up: SSM group was 38.2 months ± 26.3 months; NSM was 25.3months ±
18.8 months
• 2001 to 2012
Participants Inclusion criteria
◦ Subpopulation of 60 participants from 527 who underwent SSM or NSM
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Burdge 2013 (Continued)
◦ Prior radiotherapy was not an exclusion criteria: 5 participants had
previously elected to undergo breast-conserving therapy and subsequently elected
NSM or SSM after a new diagnosis of DCIS
Exclusion criteria
◦ Locally advanced disease with involvement of the skin
◦ Inflammatory breast cancer
◦ Collagen-vascular disease
◦ Known to smoke within the previous 6 months
Interventions • Intervention group:
◦ NSM
• Control group:
◦ SSM
• Both groups:
◦ 60 participants were identified with either locally advanced disease that
underwent neoadjuvant chemotherapy followed by SSM or NSM with immediate
reconstruction and prior or subsequent radiotherapy
Outcomes • Local recurrence
• Cosmetic results by personal opinion
Notes Only participants with advanced disease
Risk of bias
Bias Authors’ judgement Support for judgement
SelectionBias -Was the allocation sequence
adequately generated?
High risk Retrospective cohort study
Selection Bias - Was the allocation ade-
quately concealed?
High risk Retrospective cohort study
Selection Bias - Were baseline characteris-
tics similar?
High risk Baseline characteristics of the intervention
and control groups were different
There were significant differences in age
and stage between groups with younger
participants in the NSM group and more
advanced disease in the SSM group
Selection Bias - Was there adequate adjust-
ment for confounding?
High risk There was no adjustment for confounding
Performance/detection bias - Was knowl-
edge of the allocated interventions ade-
quately prevented during the study?
High risk The lack of blinding may have influenced
the results for some outcomes. Time-to-
event outcomes are generally more objec-
tive and therefore less likely to be prone
to bias. Surgical reports, however, could
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Burdge 2013 (Continued)
be influenced by knowledge of the proce-
dure. The lack of blinding may have in-
fluenced the results for some outcomes.
Cosmesismeasurementswere based on self-
report and therefore could be prone to bias
Attrition bias - Were incomplete outcome
data adequately addressed?
Unclear risk It was not mentioned in the methods sec-
tion
Reporting bias - Were reports of the study
free from selective outcome reporting?
Low risk They were defined in the methods section
of the paper
Reporting Bias - Were reports of the study
free from selective analysis reporting?
Low risk The analyses were reported as pre-defined
in the methods section of the paper
Gerber 2009
Methods • Prospective cohort study
• Conducted at the Department of Obstetrics and Gynecology, University of
Rostock and Institute of Medical Informatics and Biometry, University of Rostock,
Rostock, Germany
• 246 participants selected with an indication for MRM, no skin involvement, and
tumour margins of greater than 2 cm from the nipple.
• Intervention group: 60 NSM
• Control group:
◦ 48 SSM
◦ 130 MRM
• Follow-up 101 months (range 26 to 156)
• 8 participants were lost for unknown reasons during follow-up.
• 1994 to 2000
Participants Inclusion criteria
• Informed consent signed
• Breast cancer confirmed by pathological methods
• Selected participants with an indication for MRM
• The SSM procedure was offered to participants. The participants chose one
surgical approach over the other for aesthetic reasons.
• Intraoperative biopsies of mammary gland specimens resected from below the
nipple-areola complex (NAC) confirmed that both the NAC and the skin were not
cancerous to perform the NSM procedure. If it was positive the SSM was performed.
Exclusion criteria
• Skin involvement
• Tumour margins of greater than 2 cm from the nipple
Interventions • Intervention group:
◦ NSM
• Control group:
◦ SSM
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Gerber 2009 (Continued)
◦ MRM
In addition to surgery, participants in all groups received adjuvant treatment according
to AJCC staging
Outcomes • Local-regional recurrence (LR) was defined as histologically proven recurrent
tumour occurring in either the ipsilateral breast skin, the NAC, or in the chest wall after
MRM and tumour spread in the internal mammary, supraclavicular, infraclavicular,
ipsilateral axillary nodes, or in the non breast skin of the ipsilateral chest wall.
• Distant Metastases (DM) - all other sites of tumour recurrence.
• Breast cancer-specific deaths were included for the analyses of the overall survival
(OS) end point
• Cosmetic results by personal opinion
Notes Insufficient reporting of data to estimate the hazard ratio for overall survival analyses
Risk of bias
Bias Authors’ judgement Support for judgement
SelectionBias -Was the allocation sequence
adequately generated?
High risk Non-random method was used
Selection Bias - Was the allocation ade-
quately concealed?
High risk No method of allocation was used. It was
chosen by participants
Selection Bias - Were baseline characteris-
tics similar?
High risk Baseline age was different between inter-
vention groups (P = 0.001). Differences in
tumour stagewere apparent (e.g.% tumour
stage 1 was 18.3 for NSM group, 22.9 for
SSM group and 26.9 for MRM group), al-
though not statistically significant (P = 0.
47). The MRM group had fewer partici-
pants with adjuvant chemotherapy (83%
MRM vs 90% NSM and 88% SSM) and
radiotherapy (24% MRM vs 29% NSM
and 27% SSM)
Selection Bias - Was there adequate adjust-
ment for confounding?
High risk There was no adjustment for confounding
Performance/detection bias - Was knowl-
edge of the allocated interventions ade-
quately prevented during the study?
High risk The lack of blinding may have influenced
the results for some outcomes. Time-to-
event outcomes are generally more objec-
tive and therefore less likely to be prone to
bias. Surgical reports, however, could be in-
fluenced by knowledge of the procedure
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Attrition bias - Were incomplete outcome
data adequately addressed?
Low risk Missing outcome measures were unlikely
to bias the results. 8 participants were lost
to follow-up for unknown reasons
Reporting bias - Were reports of the study
free from selective outcome reporting?
Low risk The outcomes were not selectively reported
Reporting Bias - Were reports of the study
free from selective analysis reporting?
Low risk There was no evidence that analyses were
selectively reported - analyses were pre-de-
fined in the methods section
Horiguchi 2001
Methods • Retrospective cohort
• Conducted at the Second Department of Surgery and Department of Emergency
and Critical Care Medicine, Gunma University Faculty of Medicine, Japan
• 1041 participants
• Intervention group: 131 NSM
• Control Group: 910 MRM
• Follow-up: NSM group was 66 months and MRM was 88 months
• 1983-1999
Participants Inclusion criteria
• Breast cancer confirmed by pathological methods
• Intraoperative biopsies of mammary gland specimens resected from below the
nipple-areola complex (NAC) confirmed that both the NAC and the skin were not
cancerous to perform the NSM procedure. If it was positive the SSM was performed.
Exclusion criteria
• participants who underwent a non curative surgery
Interventions • Intervention group:
◦ NSM
• Control group:
◦ MRM
• Both groups:
◦ In addition to surgery, participants in both groups received adjuvant
treatment as recommended by Breast cancer Japanese Society
◦ Chemotherapy regimens
⋄ Before 1990 consisting of 5-fluorouracil and cyclophosphamide and
mitomycin
⋄ After 1990 consisting of 5-fluorouracil for lymph node negative and 5-
fluorouracil and cyclophosphamide followed by UFT (mixed compound of tegafur and
URACIL)
◦ No participants received radiotherapy
◦ Hormonal therapy was indicated for oestrogen receptor-positive and/or
progesterone receptor-positive participants
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Outcomes • Overall survival
• Local recurrence
Notes • The groups were different in age, stage, nodal status. Methods to adjust for
confounders were performed
• Insufficient reporting of data to estimate the hazard ratio for overall survival
analyses
Risk of bias
Bias Authors’ judgement Support for judgement
SelectionBias -Was the allocation sequence
adequately generated?
High risk Retrospective cohort study
Selection Bias - Was the allocation ade-
quately concealed?
High risk Retrospective cohort study
Selection Bias - Were baseline characteris-
tics similar?
High risk Baseline characteristics of the intervention
and control groups were different
There were significant differences in age
and stage between groups with younger
participants in the NSM group and more
advanced disease in the MRM group
Selection Bias - Was there adequate adjust-
ment for confounding?
High risk The HR for local recurrence was adjusted
for age, lymph node status and oestrogen
receptor status using a multivariable Cox
proportional hazards model. Participants
did not have radiotherapy. Tumour stage,
surgical techniques and chemotherapywere
not adjusted for
Performance/detection bias - Was knowl-
edge of the allocated interventions ade-
quately prevented during the study?
High risk The lack of blinding may have influenced
the results for some outcomes. Time-to-
event outcomes are generally more objec-
tive and therefore less likely to be prone to
bias. Surgical reports, however, could be in-
fluenced by knowledge of the procedure
Attrition bias - Were incomplete outcome
data adequately addressed?
Unclear risk It was not mentioned in the methods sec-
tion
Reporting bias - Were reports of the study
free from selective outcome reporting?
Low risk There was no evidence that outcomes were
selectively reported
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Reporting Bias - Were reports of the study
free from selective analysis reporting?
Low risk There was no evidence that analyses were
selectively reported
Kim 2010
Methods • Retrospective cohort study
• Conducted at the Departments of Surgery and Plastic Surgery, College of
Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea
• 2420 participants
• All participants had breast cancer (Stage 0 - 3a)
• Intervention group: 152 NSM
• Control group:
◦ 368 SSM
◦ 1990 MRM
• Follow-up - NSM group was 60 months and SSM was 67 months. The follow-up
of MRM was not described
• 2001 to 2006
Participants Inclusion criteria
• The indications for SSM or NSM were any stage, any tumour size, and any
tumour areola distance with indications for mastectomy.
• Participants with a clinically normal nipple and no skin involvement were offered
the option of NSM
Exclusion criteria
• Not mentioned
Interventions • Intervention group:
◦ NSM - The procedure involved 2 types of skin incision
⋄ A periareola skin incision and a lateral extension
⋄ The other was a lateral incision without a periareola skin incision
⋄ The NAC dissection was done by monopolar cautery using a low level
of cutting current. A thin layer of glandular tissue was taken from under the areola for
frozen sectioning
⋄ The NAC was preserved when palpation, shape, and colour of the
nipple were normal and when NAC ducts were confirmed as tumour-free in frozen
biopsies.
• Control groups:
◦ SSM
◦ MRM - The procedure involved an areola incision with lateral extension
• Both groups:
◦ All reconstructive procedures were performed by a single plastic surgeon
using a TRAM flap reconstruction.
◦ Adjuvant systemic treatment was performed according to the contemporary
recommendations of the St. Gallen consensus meeting and NCCN guidelines
irrespective of the surgical method.
Outcomes • Overall survival
• Local recurrence
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• Distant recurrence
Notes Specific methods were used to adjust for potential confounders
Risk of bias
Bias Authors’ judgement Support for judgement
SelectionBias -Was the allocation sequence
adequately generated?
High risk Retrospective cohort study
Selection Bias - Was the allocation ade-
quately concealed?
High risk Retrospective cohort study
Selection Bias - Were baseline characteris-
tics similar?
High risk Baseline characteristics of the intervention
and control groups were different
There were apparent differences in tumour
stage between intervention and control
groups, e.g. % tumour stage 1 was 46.1 for
NSM, 40.8 for SSM and 26.7 for MRM.
Mean baseline age waswithin 2 years differ-
ence between NSM and SSM groups (41.
5 years vs 42.8 years respectively), but was
not reported in theMRM group. Adjuvant
chemotherapy and radiotherapy use were
not reported
Selection Bias - Was there adequate adjust-
ment for confounding?
High risk The HR for overall survival was adjusted
for age, tumour stage and oestrogen recep-
tor status using amultivariableCoxpropor-
tional hazards model. Radiotherapy, surgi-
cal techniques and chemotherapy were not
adjusted for
Performance/detection bias - Was knowl-
edge of the allocated interventions ade-
quately prevented during the study?
High risk The lack of blinding may have influenced
the results for some outcomes. Time-to-
event outcomes are generally more objec-
tive and therefore less likely to be prone to
bias. Surgical reports, however, could be in-
fluenced by knowledge of the procedure
Attrition bias - Were incomplete outcome
data adequately addressed?
Unclear risk It was not specified in the methods section
Reporting bias - Were reports of the study
free from selective outcome reporting?
Low risk There was no evidence that outcomes were
selectively reported
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Reporting Bias - Were reports of the study
free from selective analysis reporting?
Low risk There was no evidence that analyses were
selectively reported (e.g. analyses were de-
fined in the methods section of the paper)
Oura 1994
Methods • Retrospective cohort study
• 493 participants
• Intervention group: 299 NSM
• Control group: 194 MRM
• All participants had breast cancer (Stage I-II)
• Follow-up
◦ Stage 1 - 49 months for NSM and 85 months for MRM
◦ Stage 2 - 38 months for NSM and 73 months for MRM
• 1993
Participants Inclusion criteria
• Stage I and II
Exclusion criteria
• Not mentioned
Interventions • Intervention group:
◦ NSM
• Control group:
◦ MRM
• Both groups:
◦ In both groups, immunochemical endocrine therapy was enforced as an
adjuvant therapy depending on the degree of lymph node metastasis and progress.
◦ participants in all groups received adjuvant treatment according to stage
Outcomes • Overall survival
• Local recurrence
Notes • No radiotherapy
• Data extraction was completed separately by two authors (Dr Maki Kawasaki, and
Dr Rintaro Mori) from The Japanese Cochrane Centre
• Insufficient reporting of data to estimate the hazard ratio for overall survival
analyses
Risk of bias
Bias Authors’ judgement Support for judgement
SelectionBias -Was the allocation sequence
adequately generated?
High risk This was a retrospective study using data
from case notes
Selection Bias - Was the allocation ade-
quately concealed?
High risk This was a retrospective study using data
from case notes
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Oura 1994 (Continued)
Selection Bias - Were baseline characteris-
tics similar?
High risk There were differences in baseline char-
acteristics between groups. Mean ages for
those with stage 1 and stage 2 tumours
respectively were 49 and 48 in the NSM
group and 56 and 54 in the MRM group.
81.6% had stage 1 tumours in the NSM
group vs 63.9% in the MRM group. Adju-
vant chemotherapy was not reported. No
participants underwent radiotherapy
Selection Bias - Was there adequate adjust-
ment for confounding?
High risk There was no adjustment for confounders
Performance/detection bias - Was knowl-
edge of the allocated interventions ade-
quately prevented during the study?
High risk The lack of blinding may have influenced
the results for some outcomes. Time-to-
event outcomes are generally more objec-
tive and therefore less likely to be prone to
bias. Surgical reports, however, could be in-
fluenced by knowledge of the procedure
Attrition bias - Were incomplete outcome
data adequately addressed?
Unclear risk It was not specified in the methods section
Reporting bias - Were reports of the study
free from selective outcome reporting?
Unclear risk There was no protocol and the definitions
of outcomeswere not provided in themeth-
ods section
Reporting Bias - Were reports of the study
free from selective analysis reporting?
Unclear risk The analyses of outcomes were not pre-
specified in the methods section of the
study report
Poruk 2015
Methods • Retrospective cohort study
• Conducted at the Huntsman Cancer Institute at the University of Utah, USA
• 261 participants
• All participants underwent mastectomy for either the treatment or prophylaxis of
breast cancer
• Intervention groupL 130 NSM
• Control Group: 131 SSM
• Follow-up: the NSM group had 25.8 months and SSM had 29 months of follow-
up
• 2005 to 2011
Participants Inclusion criteria
• Participants who underwent a NSM or SSM between April 2005 and April 2011
• Did not mention the indication for NSM
Exclusion criteria
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• Was not mentioned
Interventions • Intervention group:
◦ NSM
◦ 130 participants
◦ 25 for prophylactic reasons
• Control group:
◦ SSM was defined as any mastectomy with a skin island (as measured by the
pathologist) of less than 10 cm
◦ 131 participants
◦ 11 for prophylactic reason
• Both groups:
◦ In addition to surgery, participants in all groups received adjuvant treatment
according to AJCC staging
Outcomes • Local recurrence
• Overall survival
• Distance metastases
Notes The groups were different in age and stage. Methods to adjust for these confounders
were performed
Risk of bias
Bias Authors’ judgement Support for judgement
SelectionBias -Was the allocation sequence
adequately generated?
High risk Retrospective cohort study
Selection Bias - Was the allocation ade-
quately concealed?
High risk Retrospective cohort study
Selection Bias - Were baseline characteris-
tics similar?
High risk Baseline characteristics of the intervention
and control groups were different
There were significant differences in stag-
ing and age between groups with more ad-
vanceddisease in the SSMgroup, andNSM
groupwere younger. There were differences
in adjuvant chemotherapy and use of radio-
therapy between the intervention and con-
trol groups
Selection Bias - Was there adequate adjust-
ment for confounding?
High risk The study controlled for age, stage, and
surgery laterality. Chemotherapy and ra-
diotherapy were not adjusted for
Performance/detection bias - Was knowl-
edge of the allocated interventions ade-
quately prevented during the study?
High risk The lack of blinding may have influenced
the results for some outcomes. Time-to-
event outcomes are generally more objec-
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tive and therefore less likely to be prone to
bias. Surgical reports, however, could be in-
fluenced by knowledge of the procedure
Attrition bias - Were incomplete outcome
data adequately addressed?
Unclear risk It was not mentioned in the methods sec-
tion
Reporting bias - Were reports of the study
free from selective outcome reporting?
Low risk The outcomes were free from selective re-
porting - all relevant outcomes in themeth-
ods section were reported in the results sec-
tion
Reporting Bias - Were reports of the study
free from selective analysis reporting?
Low risk The reported analyses were defined in the
methods section of the paper
Sakurai 2013
Methods • Retrospective cohort study
• Conducted at the Kihoku Hospital, Wakayama Medical University, Wakayama,
Japan
• 932 participants
• Intervention group: 788 NSM
• Control group: 144 MRM
• The median follow-up was 78 months
• 1985-2004
Participants Inclusion criteria
• Breast cancer confirmed by pathological methods
• The NSM procedure was offered to participants. The participants chose one
surgical approach over the other for aesthetic reasons.
• Intraoperative biopsies of mammary gland specimens resected from below the
nipple-areola complex (NAC) confirmed that both the NAC and the skin were not
cancerous to perform the NSM procedure.
• Participants were reached by phone to sign a verbal informed consent. Written
consent was not obtained.
Exclusion criteria
• Not mentioned
Interventions • Intervention group:
◦ NSM
• Control group:
◦ MRM
• Both groups:
◦ Did not provide information about adjuvant chemotherapy and hormone
therapy
Outcomes • Overall survival
• Disease-free survival
• Local recurrence
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Notes None of participants in the NSM cohort received radiotherapy
Risk of bias
Bias Authors’ judgement Support for judgement
SelectionBias -Was the allocation sequence
adequately generated?
High risk Non-random method was used
Selection Bias - Was the allocation ade-
quately concealed?
High risk Non-randomised study
Selection Bias - Were baseline characteris-
tics similar?
High risk Baseline characteristics of the intervention
and control groups were different between
intervention and control groups. E.g.% tu-
mour stage 2 was 46.3 in the NSM group
and 24.3% in the MRM group. Mean age
was 51 in the NSM group vs 58 in the
MRM group. Adjuvant chemotherapy and
radiotherapy use were not reported
Selection Bias - Was there adequate adjust-
ment for confounding?
High risk There was no adjustment for potential con-
founders
Performance/detection bias - Was knowl-
edge of the allocated interventions ade-
quately prevented during the study?
High risk The lack of blinding may have influenced
the results for some outcomes. Time-to-
event outcomes are generally more objec-
tive and therefore less likely to be prone to
bias. Surgical reports, however, could be in-
fluenced by knowledge of the procedure
Attrition bias - Were incomplete outcome
data adequately addressed?
Unclear risk Not specified in the paper
Reporting bias - Were reports of the study
free from selective outcome reporting?
Low risk There was no evidence that outcomes were
selectively reported
Reporting Bias - Were reports of the study
free from selective analysis reporting?
Low risk For each outcome, there was no evi-
dence that analyses were selectively re-
ported (analyses were defined in the meth-
ods section of paper)
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Shi 2012
Methods • Retrospective cohort study
• Conducted at the Department of Breast Surgery, The first Hospital, Jilin
University, Japan
• 135 participants
• Intervention group: 35 NSM
• Control group: 100 MRM randomly selected
• 2000 to 2008
• Follow-up was performed over the telephone or during an outpatient clinic visit.
• All participants were followed up over the course of 10 to 104 months.
• The median follow-up time was 68 months.
• In total, 23 participants were followed for more than 54 months.
Participants Inclusion criteria
• Informed consent signed
• Breast cancer confirmed by pathological methods
• The NSM procedure was offered to participants. The participants chose one
surgical approach over the other for aesthetic reasons.
• Intraoperative biopsies of mammary gland specimens resected from below the
nipple-areola complex (NAC) confirmed that both the NAC and the skin were not
cancerous to perform the NSM procedure.
Exclusion criteria
• Cases with evidence of distant metastasis were excluded from the study.
Interventions • Intervention group:
◦ NSM
◦ Three types of incision were used:
an S-shaped incision ending at the inferior border of the breast parallel
to the areola
a fusiform incision with a radial incision to the areola extending in the direction of the
axilla on the lateral breast
an arc-shaped incision parallel to the axillary fold.
• Control group:
◦ MRM - the breast skin was then moved upward to the inferior clavicle
margin and downward to the superior border of rectus abdominis, internal to the
parasternal line and external to the leading edge of the latissimus dorsi muscle. The
fascia was peeled from the surface of the pectoralis major muscle, and the prosthesis
was implanted between the pectoralis major and pectoralis lesser. Axillary fat and
lymph nodes were removed
• Both groups:
In addition to surgery, participants in both groups received adjuvant treatment as rec-
ommended by the National Comprehensive Cancer Network (NCCN) guidelines, in-
cluding:
◦ chemotherapy regimens consisting of FAC (5-fluorouracil + adriamycin +
cyclophosphamide), TAC (taxol + adriamycin + cyclophosphamide), or CMF
(cyclophosphamide + methotrexate + 5-fluorouracil)
◦ radiotherapy with a total dose of 50 Gy in 25 fractions was optimal for all
participants in the study group. In the control group, participants with tumours ≥ 3
cm in diameter and metastatic axillary lymph nodes were treated with radiotherapy
◦ hormonal therapy was indicated for oestrogen receptor-positive and/or
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progesterone receptor-positive participants
Outcomes • Overall survival
• Local recurrence
• Distant recurrence
• Adverse events
• Cosmetic results
• Quality of life
Notes • All participants in the intervention group (NSM) received radiotherapy
• Insufficient reporting of data to estimate the hazard ratio for overall survival
analyses
Risk of bias
Bias Authors’ judgement Support for judgement
SelectionBias -Was the allocation sequence
adequately generated?
High risk A retrospective cohort study
Selection Bias - Was the allocation ade-
quately concealed?
High risk A retrospective cohort study
Selection Bias - Were baseline characteris-
tics similar?
High risk Baseline characteristics of the intervention
and control groups were different
There were significant differences in stag-
ing and age between groups with more ad-
vanced disease and younger participants in
the SSM group when compared to NSM.
Adjuvant chemotherapy was not reported.
All participants underwent radiotherapy
Selection Bias - Was there adequate adjust-
ment for confounding?
High risk There was no adjustment for confounding
Performance/detection bias - Was knowl-
edge of the allocated interventions ade-
quately prevented during the study?
High risk The lack of blinding may have influenced
the results for some outcomes. Time-to-
event outcomes are generally more objec-
tive and therefore less likely to be prone
to bias. Surgical reports, however, could
be influenced by knowledge of the proce-
dure. Quality of life and cosmesis measure-
ments were based on self-report and there-
fore could be prone to bias
Attrition bias - Were incomplete outcome
data adequately addressed?
Unclear risk It was not mentioned in the methods sec-
tion
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Reporting bias - Were reports of the study
free from selective outcome reporting?
Low risk There was no evidence that outcomes were
selectively reported
Reporting Bias - Were reports of the study
free from selective analysis reporting?
Low risk There was no evidence that there was selec-
tive reporting of analyses
Stanec 2014
Methods • Retrospective cohort study
• Conducted at the Department of Plastic, Reconstructive and Aesthetic Surgery,
University Hospital Dubrava, Zagreb, Croatia
• 361 participants
• All participants underwent mastectomy for breast cancer treatment and
prophylactic reasons (47 participants)
• Intervention group: 252 NSM
• Control group: 109 SSM
• Follow-up: mean 63 months
• 1997 to 2012
Participants Inclusion criteria
• Breast cancer confirmed by pathological methods
• The NSM procedure was offered to participants. The participants chose one
surgical approach over the other for aesthetic reasons.
• Intraoperative biopsies of mammary gland specimens resected from below the
nipple-areola complex (NAC) confirmed that both the NAC and the skin were not
cancerous to perform the NSM procedure
Exclusion criteria
• Not mentioned
Interventions • Intervention group:
◦ NSM
◦ Autologous reconstruction with latissimus dorsi flap (LD)
• Control group:
◦ SSM
• Both groups:
◦ Did not mention adjuvant therapy
Outcomes • Overall survival
• Local recurrence
• Adverse events
• Cosmetic results
Notes • Cosmetic results were evaluated by personal opinion
• We contacted the study author to provide the absolute number of complications
• Insufficient reporting of data to estimate the hazard ratio for overall survival
analyses
Risk of bias
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Bias Authors’ judgement Support for judgement
SelectionBias -Was the allocation sequence
adequately generated?
High risk Retrospective cohort study
Selection Bias - Was the allocation ade-
quately concealed?
High risk Retrospective cohort study
Selection Bias - Were baseline characteris-
tics similar?
High risk Baseline characteristics of the intervention
and control groups were different. E.g. tu-
mour stage 2was 34.2% in theNSMgroup
and 21.9% in the SSM group. Mean age
was 50.9 in the NSM group vs 53.2 in the
SSM group. Adjuvant chemotherapy and
radiotherapy use were not reported
Selection Bias - Was there adequate adjust-
ment for confounding?
High risk No adjustment was made for confounders
Performance/detection bias - Was knowl-
edge of the allocated interventions ade-
quately prevented during the study?
High risk The lack of blinding may have influenced
the results for some outcomes. Time-to-
event outcomes are generally more objec-
tive and therefore less likely to be prone
to bias. Surgical reports, however, could be
influenced by knowledge of the procedure.
Cosmesismeasurementswere based on self-
report and therefore could be prone to bias
Attrition bias - Were incomplete outcome
data adequately addressed?
Unclear risk Outcomes were unavailable for around
12% of participants This could be high
enough to influence results
Reporting bias - Were reports of the study
free from selective outcome reporting?
Low risk There was no evidence that outcomes were
selectively reported
Reporting Bias - Were reports of the study
free from selective analysis reporting?
Low risk There was no evidence that analyses were
selectively reported
AJCC: American Joint Committee on Cancer
DCIS: ductal carcinoma in situ
DFS: disease-free survival
DM: distant metastases
LR: local recurrence
MRM: modified radical mastectomy
NAC: nipple areolar complex
NSM: nipple-sparing mastectomy
SSM: skin-sparing mastectomy
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TM: total mastectomy
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Algaithy 2012 Case series
Alperovich 2014 Case series
Babiera 2010 Case series
Benediktsson 2008 Case series
Caruso 2006 Case series
Chattopadhyay 2014 Case series
Crowe 2008 Case series
de Alcantara Filho 2011 Case series
Eisenberg 2014 Case series
Fortunato 2013 Case series
Garcia-Etienne 2009 Case series
Garwood 2009 Case series
Jensen 2011 Case series
Leclère 2014 Case series
Lohsiriwat 2013 Case series
Maxwell 2011 Case series
Missana 2007 Case series
Munhoz 2013 Case series
Nava 2012 Case series
Ohno 2013 Case series
Paepke 2009 Case series
Peled 2014 Case series
50Nipple- and areola-sparing mastectomy for the treatment of breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Petit 2003 Case series
Petit 2006 Case series
Petit 2009b Case series/duplicate database
Petit 2012 Case series/duplicate database
Rache Simmons 2004 Case series
Radovanovic 2010 Case series
Reefy 2010 Case series
Regolo 2008 Case series
Rusgby 2010 Case series
Sachinni 2006 Case series
Salgarello 2010 Case series
Schneider 2012 Case series
Sookhan 2008 Case series
Spear 2011 Case series
Stolier 2008 Case series
Tancredi 2013 Case series
Voltura 2008 Case series
Wagner 2012 Case series
Wijayanayagam 2008 Case series
Characteristics of studies awaiting assessment [ordered by study ID]
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Seki 2015
Methods • Retrospective cohort study
• Keio University Hospital, Tokyo, Japan
• 678 participants. Propensity score was used to reduce the selection bias and matched only 66 participants in
each group
• All participants underwent mastectomy for breast cancer treatment
• Intervention group: 121 NSM
• Control group: 557 total mastectomy (TM)
• Follow-up: mean 28 months for NSM and 43 for TM
• 2003 to 2013
Participants Inclusion criteria
• Stage 0-3 breast cancer
• NSM eligible criteria: patient without indication for breast conservative surgery by magnetic resonance
imaging, ultrasonography and mammography
• Intraoperative biopsies of mammary gland specimens resected from below the nipple-areola complex (NAC)
confirmed that both the NAC and the skin were not cancerous to perform the NSM procedure.
Exclusion criteria
• Suspicion of involvement neoplastic of NAC
Interventions • Intervention group:
◦ NSM: 66
• Control group:
◦ MRM: 66
• Both groups:
◦ Both groups:In addition to surgery, participants in all groups received adjuvant treatment according to
AJCC staging
Outcomes • Overall survival
• Local recurrence
• Adverse events
Notes
Shimo 2015
Methods • Retrospective cohort study
• Department of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kanagawa, Japan
• 1218 participants
• All participants underwent mastectomy for breast cancer treatment and prophylactic reasons (47 participants)
• Intervention group: 413 NSM
• Control group: 878 TM
• Follow-up: mean 46.8 months for NSM and 51.3 for TM
• 2000 to 2013
Participants Inclusion criteria
• Stage 0-3 breast cancer
• NSM eligible criteria: patient without indication for breast conservative surgery and no clinical or image
(MRI) suspected of involvement neoplastic of NAC and patient preference.
• Intraoperative biopsies of mammary gland specimens resected from below the nipple-areola complex (NAC)
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confirmed that both the NAC and the skin were not cancerous to perform the NSM procedure
Exclusion criteria
• Suspicion of involvement neoplastic of NAC
Interventions • Intervention group:
◦ NSM: 413
• Control group:
◦ MRM: 878
• Both groups:
◦ Both groups:In addition to surgery, participants in all groups received adjuvant treatment according to
AJCC staging
Outcomes • Overall survival
• Local recurrence
• Adverse events
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Overall survival
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 NSM vs SSM - overall survival 2 781 Hazard Ratio (Fixed, 95% CI) 0.70 [0.28, 1.72]
2 NSM vs MRM - overall survival 2 1202 Hazard Ratio (Fixed, 95% CI) 0.72 [0.46, 1.13]
Comparison 2. Local recurrence
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 NSM vs MRM - local recurrence 2 1303 Hazard Ratio (Fixed, 95% CI) 0.28 [0.12, 0.68]
Comparison 3. Adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall complication 2 1067 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.01, 0.82]
2 Skin necrosis 4 1948 Risk Ratio (IV, Random, 95% CI) 4.22 [0.59, 30.03]
3 Infection 2 496 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.44, 2.09]
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Analysis 1.1. Comparison 1 Overall survival, Outcome 1 NSM vs SSM - overall survival.
Review: Nipple- and areola-sparing mastectomy for the treatment of breast cancer
Comparison: 1 Overall survival
Outcome: 1 NSM vs SSM - overall survival
Study or subgroup NSM SSM log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Kim 2010 152 368 -0.144 (0.66) 48.5 % 0.87 [ 0.24, 3.16 ]
Poruk 2015 130 131 -0.56 (0.64) 51.5 % 0.57 [ 0.16, 2.00 ]
Total (95% CI) 282 499 100.0 % 0.70 [ 0.28, 1.72 ]
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
NSM SSM
Analysis 1.2. Comparison 1 Overall survival, Outcome 2 NSM vs MRM - overall survival.
Review: Nipple- and areola-sparing mastectomy for the treatment of breast cancer
Comparison: 1 Overall survival
Outcome: 2 NSM vs MRM - overall survival
Study or subgroup NSM MRM log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Adam 2014 67 203 -0.67 (0.48) 22.7 % 0.51 [ 0.20, 1.31 ]
Sakurai 2013 788 144 -0.22 (0.26) 77.3 % 0.80 [ 0.48, 1.34 ]
Total (95% CI) 855 347 100.0 % 0.72 [ 0.46, 1.13 ]
Heterogeneity: Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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55Nipple- and areola-sparing mastectomy for the treatment of breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Local recurrence, Outcome 1 NSM vs MRM - local recurrence.
Review: Nipple- and areola-sparing mastectomy for the treatment of breast cancer
Comparison: 2 Local recurrence
Outcome: 1 NSM vs MRM - local recurrence
Study or subgroup NSM MRM log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Adam 2014 67 203 -1.29 (0.88) 25.8 % 0.28 [ 0.05, 1.54 ]
Horiguchi 2001 123 910 -1.251 (0.519) 74.2 % 0.29 [ 0.10, 0.79 ]
Total (95% CI) 190 1113 100.0 % 0.28 [ 0.12, 0.68 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.82 (P = 0.0048)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
NSM MRM
Analysis 3.1. Comparison 3 Adverse events, Outcome 1 Overall complication.
Review: Nipple- and areola-sparing mastectomy for the treatment of breast cancer
Comparison: 3 Adverse events
Outcome: 1 Overall complication
Study or subgroup NSM SSM and MRM Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sakurai 2013 5/788 26/144 53.0 % 0.04 [ 0.01, 0.09 ]
Shi 2012 2/35 19/100 47.0 % 0.30 [ 0.07, 1.23 ]
Total (95% CI) 823 244 100.0 % 0.10 [ 0.01, 0.82 ]
Total events: 7 (NSM), 45 (SSM and MRM)
Heterogeneity: Tau2 = 2.03; Chi2 = 6.46, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 2.14 (P = 0.033)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
NSM SSM and MRM
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Analysis 3.2. Comparison 3 Adverse events, Outcome 2 Skin necrosis.
Review: Nipple- and areola-sparing mastectomy for the treatment of breast cancer
Comparison: 3 Adverse events
Outcome: 2 Skin necrosis
Study or subgroup NSM SSM and MRM Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Kim 2010 26/152 0/368 23.4 % 127.82 [ 7.84, 2084.18 ]
Sakurai 2013 0/788 0/144 Not estimable
Shi 2012 2/35 7/100 35.0 % 0.82 [ 0.18, 3.75 ]
Stanec 2014 40/252 7/109 41.6 % 2.47 [ 1.14, 5.34 ]
Total (95% CI) 1227 721 100.0 % 4.22 [ 0.59, 30.03 ]
Total events: 68 (NSM), 14 (SSM and MRM)
Heterogeneity: Tau2 = 2.26; Chi2 = 9.70, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
NSM SSM and MRM
Analysis 3.3. Comparison 3 Adverse events, Outcome 3 Infection.
Review: Nipple- and areola-sparing mastectomy for the treatment of breast cancer
Comparison: 3 Adverse events
Outcome: 3 Infection
Study or subgroup NSM SSM and MRM Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shi 2012 2/35 3/100 13.7 % 1.90 [ 0.33, 10.93 ]
Stanec 2014 13/252 7/109 86.3 % 0.80 [ 0.33, 1.96 ]
Total (95% CI) 287 209 100.0 % 0.95 [ 0.44, 2.09 ]
Total events: 15 (NSM), 10 (SSM and MRM)
Heterogeneity: Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Tumour stage by study
Study Stage 0 Stage 1 Stage 2 Stage 3 Stage 4
Adam 2014 Study did not use the
AJCC classification
Boneti 2011 Study did not use the
AJCC classification
Burdge 2013 Study did not use the
AJCC classification
Gerber 2009 0 22 168 13 0
Horiguchi 2001 71 289 581 102 0
Kim 2010 173 752 1274 311 0
Oura 1994 0 368 125 0 0
Poruk 2015 34 70 77 34 6
Sakurai 2013 26 361 399 140 5
Shi 2012 10 0 81 14 0
Stanec 2014 73 130 71 41 0
Total 387 1992 2776 655 11
AJCC: American Joint Committee on Cancer
Table 2. Number of participants by tumour stage and intervention
Study Stage 0 Stage 1 Stage 2 Stage 3 Stage 4
NSM; SSM; MRM NSM; SSM; MRM NSM; SSM; MRM NSM; SSM; MRM NSM; SSM; MRM
Adam 2014 This study did not use the AJCC classification
Boneti 2011 This study did not use the AJCC classification
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Table 2. Number of participants by tumour stage and intervention (Continued)
Burdge 2013 This study did not use the AJCC classification
Gerber 20091 11(18.3);11(22.9)
;35 (26.9)
44(73.3);36(75.0)
;88(67.7)
5(8.3);1(2.1);7(5.4) 0;0;0
Horiguchi 20012 19(14.3); 0;52(5.7) 64(48.1); 0;225(24.
7)
48(36.1); 0; 533(58.
6)
2(1.5); 0; 100(11.0) 0;0;0
Kim 20103 19(12.5);65(17.7);
89(4.5)
70(46.1); 150 (40.8)
;532(26.7)
55(36.2);121(32.9)
;1098(55.2)
8(5.3);32(8.7)271
(13.6)
0;0;0
Oura 1994 0;0;0 244(81.6); 0; 124
(63.9)
55(18.4); 0; 70(36.
1)
0;0;0 0;0;0
Poruk 20154 24(23.3); 10 (8.5); 0 36(35.0); 34(28.8);
0
34(33.0); 43(36.4);
0
7(6.8); 27(22.9);0 2(1.9);4(3.4); 0
Sakurai 2013 21(2.7); 0; 5(3.5) 304(38.6); 0; 57(39.
6)
364(46.3); 0; 35(24.
3)
95(12.1); 0; 45(31.
3)
3(0.4); 0; 2(1.4)
Shi 2012 2 (5.7); 0; 8 (8.0) 10 (28.6); 0; 20(20) 18 (51.4); 0; 63 (63.
0)
5(14.3); 0; 9(9.0) 0;0;0
Stanec 2014 51(19.8); 22(22.9);
0
97(37.7);33(34.4);0 88(34.2); 21(21.9);
0
21(8.2); 20 (20.8); 0 0;0;0
Total 136(7.4); 97(15.4)
;154(4.4)
836(45.8);228(36.
2);993(28.6)
706(38.7);221(35.
1);1887(54.4)
143(7.8);80(12.7);
432(12.5)
5(0.3); 4(0.6); 2(0.
1)
Numbers are given by absolute values with percentages in brackets.
AJCC: American Joint Committee on Cancer
MRM: modified radical mastectomy
NSM: nipple-sparing mastectomy
SSM: skin-sparing mastectomy
1Stage 0 and 1 have been combined; P = 0.47
2P < 0.01
3P = 0.21
4P = 0.001
Table 3. Mean age of participants by intervention
Age NSM SSM MRM Comments
Adam 2014 49
(24-74)
- 48.5
(21-87)
P = 0.38
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Table 3. Mean age of participants by intervention (Continued)
Boneti 2011 51.2
(10.9)
53,1
(11.5)
- P = 0.24
Burdge 2013 48.1
(10.4);
(29-75)
53.9
(10.4);
(29-73)
-
Gerber 2009 46
(10)
48
(10)
58
(6)
P = 0.001
Horiguchi 2001 <= 50 y: 57
>50 y: 76
- <= 50 y: 504
50 y >: 406
P < 0.01
Kim 2010 41.5
(7.4)
42.8
(6.6)
data not available P = 0.06
Oura 1994 Stage 1: 49
Stage 2: 48
- Stage 1: 56
Stage 2: 54
Poruk 2015 45
(12)
55
(14.5)
- P < 0.001
Sakurai 2013 51
(25-89)
- 58
(31-88)
Shi 2012 35.6 - 50.8
Stanec 2014 50.9 53.2 -
MRM: modified radical mastectomy
NSM: nipple-sparing mastectomy
SSM: skin-sparing mastectomy
Table 4. Mean follow-up (in months) by intervention
Follow-up
(months)
NSM SSM MRM Comments
Adam 2014 35 - 36
Boneti 2011 25.3
(18.8)
3-102
38.2
(26.3)
4-144
- P < 0.001
Burdge 2013 25
(18.8)
38
(26.3)
-
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Table 4. Mean follow-up (in months) by intervention (Continued)
Gerber 2009 101
(32-126)
101
(32-126)
101
(32-126)
Horiguchi 2001 66 - 81
Kim 2010 60 67 not mentioned
Oura 1994 Stage 1: 49
Stage 2: 38
- Stage 1: 85
Stage 2: 73
Poruk 2015 25.8
(18)
29.9
(15.7)
- P = 0.86
Sakurai 2013 87
(10-252)
- 87
(0-231)
Shi 2012 68
(10-104)
- 68
(10-104)
Stanec 2014 43 58 -
MRM: modified radical mastectomy
NSM: nipple-sparing mastectomy
SSM: skin-sparing mastectomy
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Breast Neoplasms] explode all trees
#2 breast cancer or breast neoplasm or breast adenocarcinoma or breast carcinoma or breast tumour or breast tumor
#3 #1 or #2
#4 MeSH descriptor: [Mastectomy, Segmental] explode all trees
#5 MeSH descriptor: [Mastectomy, Subcutaneous] explode all trees
#6 segmental mastectom* or subcutaneous mastectom* or breast conserving surger* or partial mastectom* or nipple-sparingmastectom*
or areola-sparing mastectom* or local excision mastectom* or limited resection mastectom*
#5 #4 or #5 or #6
#6 #3 and #7
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Appendix 2. MEDLINE search strategy
# Searches
1 randomized controlled trial.pt.
2 controlled clinical trial.pt.
3 randomized.ab.
4 placebo.ab.
5 Clinical Trials as Topic/
6 randomly.ab.
7 trial.ti.
8 (crossover or cross-over).tw.
9 Pragmatic Clinical Trials as Topic/
10 pragmatic clinical trial.pt.
11 or/1-10
12 Case-Control Studies/
13 Control Groups/
14 Matched-Pair Analysis/
15 Retrospective Studies/
16 ((case* adj5 control*) or (case adj3 comparison*) or control group*).ti,ab
17 or/12-16
18 Cohort Studies/
19 Longitudinal Studies/
20 Follow-Up Studies/
21 Prospective Studies/
22 Retrospective Studies/
23 cohort.ti,ab.
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(Continued)
24 longitudinal.ti,ab.
25 prospective.ti,ab.
26 retrospective.ti,ab.
27 or/18-26
28 exp Breast Neoplasms/
29 (breast cancer or breast neoplasm or breast carcinoma or breast tumour or breast tumor).mp
30 or/28-29
31 exp Mastectomy, Segmental/
32 exp Mastectomy, Subcutaneous/
33 segmental mastectom*.mp.
34 subcutaneous mastectom*.mp.
35 breast conserving surger*.mp.
36 partial mastectom*.mp.
37 nipple-sparing mastectom*.mp.
38 areola-sparing mastectom*.mp.
39 local excision mastectom*.mp.
40 limited resection mastectom*.mp.
41 (limited resection adj5 mastectom*).mp.
42 or/31-41
43 and/30,42
44 Animals/
45 Humans/
46 44 not 45
47 43 not 46
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(Continued)
48 and/11,47
49 and/17,47
50 and/11,47
Appendix 3. Embase search strategy
#1 random* OR factorial* OR crossover* OR cross NEXT/1 over* OR placebo* OR (doubl* AND blind*) OR (singl* AND blind*)
OR assign* OR allocat* OR volunteer* OR ’crossover procedure’/exp OR ’double blind procedure’/exp OR ’randomized controlled
trial’/exp OR ’single blind procedure’/exp
#2 ’case control study’/syn OR (’case control’ OR ’case base’ OR ’case matched’ OR retrospective) NEXT/3 (analys* OR design* OR
evaluation* OR research OR stud* OR survey* OR trial*)
#3 (cohort OR concurrent OR incidence OR longitudinal OR followup OR ’follow up’ OR prospective OR retrospective) NEXT/1
(analys* OR design* OR evaluation* OR research OR stud* OR survey* OR trial*) OR ’prospective method’/exp OR ’retrospective
study’/syn
#4 ’breast neoplasms’/exp OR ’breast neoplasms’ OR ’breast cancer’/exp OR ’breast cancer’ OR ’breast carcinoma’/exp OR ’breast
carcinoma’ OR ’breast tumour’ OR ’breast tumor’/exp OR ’breast tumor’
#5 ’segmental mastectomy’/exp OR ’segmental mastectomy’
#6 ’subcutaneous mastectomy’/exp OR ’subcutaneous mastectomy’
#7 ’breast conserving surgery’/exp OR ’breast conserving surgery’
#8 ’partial mastectomy’/exp OR ’partial mastectomy’
#9 ’nipple-sparing mastectomy’
#10 ’areola-sparing mastectomy’
#11 ’local excision mastectomy’
#12 ’limited resection mastectomy’
#13 ’limited resection’ NEAR/5 mastectom*
#14 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
#15 #4 AND #14
#16 #15 AND [humans]/lim AND [embase]/lim
#17 #1 AND #16
#18 #2 AND #16
#19 #3 AND #16
Appendix 4. LILACS search strategy
Search strategy
#1(Mastectomia Segmentar) OR (Mastectomia Segmental ) OR (Mastectomy, Segmental ) OR (Lumpectomy) OR (Partial Mastec-
tomy) OR (Breast-Conserving Surgery) OR (Ex E04.466.701)
#2(Mastectomy, Subcutaneous) OR (Mastectomia Subcutânea) OR (Mastectomia Subcutânea) OR (Ex E04.466.823)
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(Continued)
#3(Breast Neoplasms) OR (Neoplasias de la Mama) OR (Neoplasias da Mama) OR (Cancer of Breast) OR (Breast Cancer) OR
(Breast Tumors)
#4 #1 OR #2
#5 #3 AND #4
Appendix 5. WHO ICTRP search portal search strategy
Basic searches
1. Nipple-sparing mastectomy AND breast cancer
2. Areola-sparing mastectomy AND breast cancer[ft1]
Advance searches
Title: Nipple and areola sparing mastectomy for the treatment of breast cancer
Recruitment Status: ALL
Condition: breast cancer
Intervention: nipple-sparing mastectomy OR areola-sparing mastectomy OR mastectomy OR breast conserving surgery OR NAC
Recruitment Status: ALL
Condition: breast cancer
Intervention: nipple AND areola AND mastectomy
Recruitment Status: ALL
Appendix 6. ClinicalTrials.gov search strategy
Basic searches
1. Nipple-sparing mastectomy AND breast cancer
2. Areola-sparing mastectomy AND breast cancer
Advance searches
Title: Nipple and areola sparing mastectomy for the treatment of breast cancer
Recruitment: All Studies
Study Results: All Studies
Study Type: All Studies
Gender: All Studies
Condition: breast cancer
Intervention: nipple-sparing mastectomy OR areola-sparing mastectomy OR mastectomy OR segmental mastectomy OR breast con-
serving surgery OR NAC
Recruitment: All Studies
Study Results: All Studies
Study Type: All Studies
Gender: All Studies
Condition: breast cancer
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Intervention: nipple AND areola AND mastectomy
Recruitment: All Studies
Study Results: All Studies
Study Type: All Studies
Gender: All Studies
H I S T O R Y
Protocol first published: Issue 1, 2011
Review first published: Issue 11, 2016
Date Event Description
9 November 2012 Amended The previous version of this protocol included nipple-, areola- and skin-sparing mastectomy for
breast cancer. Due to nipple- and areola-sparing mastectomy being different treatments to skin-
sparing mastectomy, the scope of this protocol has been revised to review nipple- and areola-sparing
mastectomy only
9 November 2012 Amended The scope of this protocol has changed to include nipple- and areola-sparing mastectomy only. In
addition, the types of studies have been extended to include non-randomised study designs
C O N T R I B U T I O N S O F A U T H O R S
Bruna Salani - background, objectives, outcome definitions and protocol organization, screened studies for inclusion, extracted data,
completed the first draft
Rachel Riera - methodological topics and protocol organization, drafted sections of the review
Marcos Desidério Ricci - screened studies for inclusion, extracted data.
Tiago B de Castria- outcome definition and statistical analysis.
Alvaro Atallah - methodological topics.
Jessica Barrett - methodological topics, statistical analysis, drafted sections of the review.
José Luiz Barbosa Bevilacqua - idealization, background, objectives and outcome definitions.
D E C L A R A T I O N S O F I N T E R E S T
BS: none known
RR: none known
MDR: none known
TBDC: none known
AA: none known
JB: none known
JLBB: none known
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S O U R C E S O F S U P P O R T
Internal sources
• None, Other.
External sources
• None, Other.
• Medical Research Council, UK.
Jessica Barrett was supported by the Medical Research Council UK grant numbers G0902100 and MR/K014811/1
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• We included study design filters to the search strategies to ensure that our search results were as relevant and comprehensive as
possible to comply with Cochrane search requirements.
• We included skin-sparing mastectomy as a comparator in this version of the review. During the data extraction process, we
identified articles that included two different control groups, that is, modified radical mastectomy and skin-sparing mastectomy. Due
to the importance of the information presented, we have chosen to present data using both types of surgeries as a comparator to
nipple-sparing mastectomy.
• Due to lack of data, it was not possible to perform subgroup analysis or comparisons of thromboembolic events as proposed
initially in the protocol. We have included the analysis of overall complications as described in most studies. This outcome also
included surgical systemic complications.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Nipples; Breast Neoplasms [mortality; ∗surgery]; Carcinoma, Intraductal, Noninfiltrating [mortality; ∗surgery]; Cohort Studies;
Mastectomy [adverse effects; ∗methods;mortality]; NeoplasmRecurrence, Local; Organ SparingTreatments [adverse effects; ∗methods];
Postoperative Complications; Skin
MeSH check words
Female; Humans
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